Armed Forces Reportable Medical Events
Guidelines and Case Definitions

Functional Proponent:
Armed Forces Health Surveillance Branch
Defense Health Agency

October 2022

Prepared in collaboration with: U.S. Air Force School of Aerospace Medicine
Army Public Health Center
Navy and Marine Corps Public Health Center
1. Amebiasis
2. Anthrax
3. Arboviral diseases
4. Babesiosis
5. Botulism
6. Brucellosis
7. Campylobacteriosis
8. Chikungunya Virus Disease
9. Chlamydia trachomatis
10. Cholera O1 or O139
11. Coccidioidomycosis
12. Cold Weather Injuries
13. COVID-19
14. Cryptosporidiosis
15. Cyclosporiasis
16. Dengue Virus Infection
17. Diphtheria
18. Escherichia coli, Shiga toxin producing
19. Ehrlichiosis and Anaplasmosis
20. Filarial Infections
21. Giardiasis
22. Gonorrhea
23. Haemophilus influenzae, Invasive
24. Hantavirus Disease
25. Heat Illness
26. Hemorrhagic Fever, Viral
27. Hepatitis A
28. Hepatitis B, acute & chronic
29. Hepatitis C, acute & chronic
30. Influenza-Associated Hospitalization
31. Legionellosis
32. Leishmaniasis
33. Leprosy
34. Leptospirosis
35. Listeriosis
36. Lyme disease

37. Malaria
38. Measles
39. Meningococcal disease
40. Mumps
41. Norovirus Infection
42. Novel and Variant Influenza
43. Outbreak or Disease Cluster
44. Pertussis
45. Plague
46. Poliomyelitis
47. Post-Exposure Prophylaxis (PEP) against Rabies
48. Q fever
49. Rabies, Human
50. Relapsing Fever
51. Rift Valley Fever
52. Rubella
53. Salmonellosis
54. Schistosomiasis
55. Severe Acute Respiratory Syndrome
56. Shigellosis
57. Smallpox
58. Spotted Fever Rickettsiosis
59. Syphilis
60. Tetanus
61. Toxic Shock Syndrome
62. Trichinellosis
63. Trypanosomiasis
64. Tuberculosis
65. Tularemia
66. Typhoid Fever
67. Typhus Fever
68. Varicella
69. Yellow Fever
70. Zika Virus
## Contents

Overview ....................................................................................................................................................... 5  
Summary of Change ...................................................................................................................................... 5  
Requirement to Report .................................................................................................................................. 6  
Selection Criteria for Reportable Medical Events ......................................................................................... 6  
Common Terminology for Reportable Medical Events ................................................................................. 7  
What Not to Report ...................................................................................................................................... 8  
Common Laboratory Acronyms .................................................................................................................... 8  
Service Points of Contact .............................................................................................................................. 9  
Disease Reporting System internet (DRSi) Web Links .................................................................................. 9  
Amebiasis (*Entamoeba histolytica*) ............................................................................................................. 10  
Anthrax (*Bacillus anthracis*) ........................................................................................................................ 11  
Arboviral Diseases, Neuroinvasive and Non-neuroinvasive ....................................................................... 13  
Babesiosis (*Babesia* species) ....................................................................................................................... 15  
Botulism (*Clostridium botulinum* toxin) .......................................................................................................... 18  
Brucellosis (*Brucella* species) .................................................................................................................... 20  
Campylobacteriosis (*Campylobacter* species) .............................................................................................. 21  
Chikungunya Virus Disease (chikungunya virus) ......................................................................................... 22  
Chlamydia Infection (*Chlamydia trachomatis*) ............................................................................................ 23  
Cholera (Cholera Toxin-Producing *Vibrio cholerae* O1 or O139) ............................................................... 24  
Coccidioidomycosis (*Coccidioides* species) .............................................................................................. 25  
Cold Weather Injuries ......................................................................................................................................... 26  
COVID-19 Associated Hospitalization and Death (SARS coronavirus-2) ..................................................... 28  
Cryptosporidiosis (*Cryptosporidium* species) ............................................................................................... 30  
Cyclosporiasis (*Cyclospora cayetanensis*) .................................................................................................... 31  
Dengue Virus Infection (dengue virus -1, -2, -3, and -4) ............................................................................. 32  
Diphtheria (*Corynebacterium diphtheriae*) ..................................................................................................... 33  
*Escherichia coli*, Shiga Toxin Producing (STEC) Infection ........................................................................... 34  
Ehrlichiosis and Anaplasmosis (*Anaplasma phagocytophilum*, *Ehrlichia chaffeensis*, *Ehrlichia ewingii*) ... 36  
Filariasis (*Wuchereria bancrofti, Brugia malayi, Brugia timori*), Loiasis (*Loa loa*), and Onchocerciasis (*Onchocerca volvulus*) ........................................................................................................... 38  
Giardiasis (*Giardia lamblia*) ....................................................................................................................... 39  
Gonorrhea (*Neisseria gonorrhoea*) .......................................................................................................... 40
<table>
<thead>
<tr>
<th>Disease/Infection</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haemophilus influenzae, Invasive (Haemophilus influenzae)</td>
<td>41</td>
</tr>
<tr>
<td>Hantavirus Disease (Bunyaviridae viruses)</td>
<td>42</td>
</tr>
<tr>
<td>Heat Illness</td>
<td>43</td>
</tr>
<tr>
<td>Hemorrhagic Fever, Viral (VHF)</td>
<td>45</td>
</tr>
<tr>
<td>Hepatitis A (hepatitis A virus)</td>
<td>46</td>
</tr>
<tr>
<td>Hepatitis B, Acute &amp; Chronic (hepatitis B virus)</td>
<td>47</td>
</tr>
<tr>
<td>Hepatitis C, Acute &amp; Chronic (hepatitis C virus)</td>
<td>48</td>
</tr>
<tr>
<td>Influenza-Associated Hospitalization (Influenza virus)</td>
<td>50</td>
</tr>
<tr>
<td>Legionellosis (Legionella species)</td>
<td>51</td>
</tr>
<tr>
<td>Leishmaniasis (Leishmania species)</td>
<td>53</td>
</tr>
<tr>
<td>Leprosy (Mycobacterium leprae)</td>
<td>54</td>
</tr>
<tr>
<td>Leptospirosis (Leptospira interrogans)</td>
<td>55</td>
</tr>
<tr>
<td>Listeriosis (Listeria monocytogenes)</td>
<td>56</td>
</tr>
<tr>
<td>Lyme Disease (Borrelia burgdorferi)</td>
<td>58</td>
</tr>
<tr>
<td>Malaria (Plasmodium species)</td>
<td>60</td>
</tr>
<tr>
<td>Measles (measles virus)</td>
<td>61</td>
</tr>
<tr>
<td>Meningococcal Disease (Neisseria meningitidis)</td>
<td>62</td>
</tr>
<tr>
<td>Mumps (mumps virus)</td>
<td>63</td>
</tr>
<tr>
<td>Norovirus Infection (Norwalk virus)</td>
<td>64</td>
</tr>
<tr>
<td>Novel and Variant Influenza (Influenza A virus)</td>
<td>65</td>
</tr>
<tr>
<td>Outbreak or Disease Cluster</td>
<td>66</td>
</tr>
<tr>
<td>Pertussis (Bordetella pertussis)</td>
<td>67</td>
</tr>
<tr>
<td>Plague (Yersinia pestis)</td>
<td>68</td>
</tr>
<tr>
<td>Poliomyelitis (poliovirus)</td>
<td>70</td>
</tr>
<tr>
<td>Post-Exposure Prophylaxis (PEP) against Rabies</td>
<td>71</td>
</tr>
<tr>
<td>Q fever (Coxiella burnetii)</td>
<td>72</td>
</tr>
<tr>
<td>Rabies, Human (Lyssavirus)</td>
<td>74</td>
</tr>
<tr>
<td>Relapsing Fever (Borrelia species)</td>
<td>75</td>
</tr>
<tr>
<td>Rift Valley Fever (RVF)</td>
<td>76</td>
</tr>
<tr>
<td>Rubella (rubella virus)</td>
<td>77</td>
</tr>
<tr>
<td>Salmonellosis (Salmonella species)</td>
<td>78</td>
</tr>
<tr>
<td>Schistosomiasis (Schistosoma species)</td>
<td>79</td>
</tr>
<tr>
<td>Severe Acute Respiratory Syndrome (SARS)</td>
<td>80</td>
</tr>
<tr>
<td>Disease</td>
<td>Page</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Shigellosis (Shigella species)</td>
<td>82</td>
</tr>
<tr>
<td>Smallpox (variola virus)</td>
<td>83</td>
</tr>
<tr>
<td>Spotted Fever Rickettsiosis (Rickettsia species)</td>
<td>84</td>
</tr>
<tr>
<td>Syphilis (Treponema pallidum)</td>
<td>86</td>
</tr>
<tr>
<td>Tetanus (Clostridium tetani)</td>
<td>90</td>
</tr>
<tr>
<td>Toxic Shock Syndrome (TSS)</td>
<td>91</td>
</tr>
<tr>
<td>Trichinellosis (Trichinella species)</td>
<td>93</td>
</tr>
<tr>
<td>Trypanosomiasis (Trypanosoma species)</td>
<td>94</td>
</tr>
<tr>
<td>Tuberculosis (Mycobacterium tuberculosis)</td>
<td>96</td>
</tr>
<tr>
<td>Tularemia (Francisella tularensis)</td>
<td>98</td>
</tr>
<tr>
<td>Typhoid Fever (Salmonella enterica serovar Typhi)</td>
<td>99</td>
</tr>
<tr>
<td>Typhus Fever (Rickettsia prowazekii, Rickettsia typhi, or Orientia tsutsugamushi)</td>
<td>100</td>
</tr>
<tr>
<td>Varicella (varicella-zoster virus)</td>
<td>102</td>
</tr>
<tr>
<td>Yellow Fever (yellow fever virus)</td>
<td>103</td>
</tr>
<tr>
<td>Zika Virus (Flavivirus)</td>
<td>105</td>
</tr>
<tr>
<td>Required Data Elements</td>
<td>107</td>
</tr>
<tr>
<td>ICD-10 Codes &amp; Synonyms</td>
<td>108</td>
</tr>
<tr>
<td>References</td>
<td>114</td>
</tr>
</tbody>
</table>
Overview

A reportable medical event may represent an inherent, significant threat to public health and military operations. These events have the potential to affect large numbers of people, to be widely transmitted within a population, to have severe/life threatening clinical manifestations, and to disrupt military training and deployment. Timely, accurate reporting of probable, suspected or confirmed cases ensures proper identification, treatment, control, and follow-up of cases.

Reportable medical events were chosen by consensus and recommendations from each of the Services about notifiable diseases from the Centers for Disease Control and Prevention (CDC), the Council of State and Territorial Epidemiologists (CSTE), and events that military public health experts have identified as representing significant military threats that deserve additional emphasis for surveillance. The principal goals of this document are to achieve data consistency and standardization of reportable events tracking across each Service, and to aid local-level reporting by providing programmatic guidance.

As part of the ongoing effort to consolidate Department of Defense (DoD) medical surveillance data, the following sections are included in this Armed Forces Reportable Medical Events Guidelines and Case Definitions document:

- Requirement to Report
- Selection Criteria for Reportable Medical Events
- Common Delineations for Reportable Medical Events
- What Not to Report
- Service Points of Contact
- Reportable Medical Event Case Definitions
- Reportable Disease ICD-10 Codes & Synonyms
- References

Summary of Change

This document represents a revision from the January 2020 version and should be read in its entirety. The following is a summary of the significant changes:

- The following conditions have been updated: Cholera (updated wording for emphasis), Diphtheria (probable case definition removed, suspected case definition added, includes criteria for non-respiratory cases), Hepatitis C (acute and chronic clinical descriptions updated, updates to laboratory requirements), Legionellosis (includes extra pulmonary, probable case definition added), Listeriosis (includes invasive and non-invasive clinical criteria, probable and suspected case definition added), Pertussis (update to laboratory criteria, removes age requirement for probable cases), Plague (additional clinical criteria included, new laboratory criteria), Salmonellosis (suspected case definition removed, probable case definition updated), Spotted Fever Rickettsiosis (updated clinical criteria, suspected case definition added, new laboratory criteria), Syphilis (updated to simplify language and added a flow chart for ease of readability), and Yellow Fever (additional clinical criteria added, new laboratory criteria).
The following conditions have been added: Babesiosis and COVID-19

### Requirement to Report

The reporting of important preventable medical events has long been a cornerstone of public health surveillance rooted in international and national regulations to prevent the introduction, transmission, and spread of communicable diseases. As such, DODD 6490.02E requires the reporting of medical events within the DoD as defined in this Guide. Specific Service and COCOM guidance specify the process by which these requirements are implemented within each Component. Reference documents include:

- DODD 6490.02E "Comprehensive Health Surveillance"
- DODI 6490.03 “Deployment Health”
- Joint Publication 4-02 "Doctrine for Health Service Support for Joint Operations"
- CJCS Memorandum MCM 0028-07 "Procedures for Deployment Health Surveillance"
- Navy Manual of the Medical Department p-117 articles 2-17 and 2-19
- BUMED INST 6220.12 series “Medical Surveillance and Medical Event Reporting”
- Army Regulations 40-5 “Medical Services Preventive Medicine”
- Department of the Army Pamphlet 40-11 “Medical Services Preventive Medicine”
- AFMAN 48-105 “Surveillance, Prevention, and Control of Diseases and Conditions of Public Health or Military Significance”
- Coast Guard Medical Manual COMDTINST M6000.1F “Chapter 7, Preventive Medicine”

This Guide represents a DoD list of reportable events of interest. Individual Services may require reporting of additional diseases and conditions. Please refer to above Service specific instructions for details. Furthermore, military medical departments may be required to report additional diseases and events to their respective country, state and/or local health departments. Refer to country Status of Forces Agreements, the directives listed above and respective state health department regulations for details.

### Selection Criteria for Reportable Medical Events

The below criteria are used collectively to decide whether a medical diagnosis or condition should be reportable or not. Not all events can be reportable as it takes a considerable amount of time and resources. All events are set against the below standards to ensure the data collected are useful within the DoD for Force Health Protection.

1. Is there a clear case definition?
2. Are there control and/or prevention measures that can be put into place or need to be tracked within the DoD?
3. Is reporting of the event the only sufficient, timely source of the necessary information?
4. Does it represent an inherent, significant threat to military public health?
5. Does it represent a significant military operational threat?
6. Does it have the potential to inform military program guidance or policy?
7. Is the tactical burden of reporting worth the time and effort?
8. Is the event commonly reportable by state or federal laws, regulations, or guidelines?
**Common Terminology for Reportable Medical Events**

**Case Definition.** In this Guide, a case definition represents the specific clinical, laboratory, and other criteria that must be met for a disease or condition to be reportable. All components of the case definition including laboratory results and/or the clinical description should be compared to the patient’s laboratory results and/or signs/symptoms to determine if the case is reportable. A clinical diagnosis by a provider does not always translate to a case meeting a surveillance case definition for reporting. Likewise, surveillance case definitions are not intended to be used by providers for making a clinical diagnosis or determining how to meet an individual patient’s health needs.

**Reportable Medical Event (RME).** A medical event or condition mandatory for reporting.

**Medical Event Report (MER).** The actual report containing information from the RME that is manually entered into the Disease Reporting System internet (DRSi).

**Background.** This section of the case definition provides descriptive information about the RME. The background includes information about the causative agent, travel risks, and clinical description.

**Case Classification.** A case classification specifies what is needed to meet the case definition of a reportable event. A case definition can be grouped into three classification categories: suspected, probable, or confirmed (Figure 1). Each case classification has its own specific set of clinical and/or laboratory criteria. Not all RMEs have all three case classifications.

![Figure 1: Depiction of Case Classification](image)

Specificity of case definition and accuracy of diagnosis increases from Left to Right

<table>
<thead>
<tr>
<th>Suspect Classification</th>
<th>Probable Classification</th>
<th>Confirmed Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Early identification of the disease is critical for disease control</td>
<td>- Case definition is usually more detailed than suspect classification</td>
<td>- Case definition is the most specific</td>
</tr>
<tr>
<td>- Case definition usually limited to clinical symptoms without lab results</td>
<td>- Does not have all the required elements for confirmed case</td>
<td>- Usually requires laboratory support</td>
</tr>
</tbody>
</table>

RMEs should be reported at the earliest case classification required and updated regularly as more clinical and/or laboratory information becomes available.

**Clinical Description.** A brief description of clinical signs and symptoms. Unless the clinical description is explicitly referenced in the Case Classification section of the case definition, it is included only as background information.
**Epidemiologically Linked (Epi-link).** A case in which the patient: (a) had contact with a confirmed or probable case, as defined by the case definition or (b) was exposed to the same source of infection as a probable or confirmed case or (c) is a member of a risk group as defined by Public Health during an outbreak.

**Critical Reporting Elements.** Additional information is sometimes required for specific MERs. Ensure the information listed in the Required Comments section of the case definition is recorded in the MER. If the information is unavailable, indicate so.

**Incident Rule.** Only incident cases are reportable. Incident cases are newly diagnosed cases in a person, regardless of how long the person has been sick.

---

**What Not to Report**

- HIV is not reportable through DRSi.
- Prevalent cases. DRSi is a reporting tool for incident cases only.

---

**Common Laboratory Acronyms**

- CIA: Chemiluminescence Immunoassay
- CF: Complement Fixation
- CSF: Cerebrospinal Fluid
- DA: Direct Agglutination
- DFA: Direct Immunofluorescent Antibody
- DNA: Deoxyribonucleic Acid
- ELISA: Enzyme Linked Immunosorbent Assay
- EIA: Enzyme Immunoassay
- FTA-ABS: Fluorescent Treponemal Antibody Absorption
- HI: Hemagglutination Inhibition
- IFA: Indirect Immunofluorescent Antibody
- IgG: Immunoglobulin antibody class G
- IgM: Immunoglobulin antibody class M
- IHA: Indirect Hemagglutination
- IHC: Immunohistochemistry
- IU/L: International Units per Liter
- LA: Latex Agglutination
- LRN: Laboratory Response Network
- MAT: Microagglutination Test
- NAAT: Nucleic Acid Amplification Test
- NAT: Nucleic Acid Test
Service Points of Contact

Consult the following individual Service points of contact with suggested changes to this Armed Forces Reportable Medical Events Guidelines and Case Definitions document and/or questions about reporting:

<table>
<thead>
<tr>
<th>Service</th>
<th>Reportable Medical Events/DRSi POC</th>
</tr>
</thead>
</table>
| Air Force | Reportable Medical Events/DRSi POC  
USAF School of Aerospace Medicine  
DSN 798-3207 (COM 937-938-3207)  
afdrsi@us.af.mil |
| Army      | Reportable Medical Events/DRSi POC  
Army Institute of Public Health  
DSN 584-7605 (COM 410-436-7605)  
usarmy.apg.medcom-aphc.mbx.disease-epidemiologyprogram13@health.mil |
| Navy/MC   | Reportable Medical Events/DRSi POC  
Navy Marine Corps Public Health Center  
DSN 377-0700 (COM 757-953-0700)  
usn.hampton-roads.navmcpubhlichenors.list.nmcphc-prgpolicysup@health.mil |
| Coast Guard | Reportable Medical Events/DRSi POC  
HQ USCG, COMDT (CG-1121)  
DSN: NA (COM 202-475-5256) |

These Guidelines are available electronically at the Armed Forces Health Surveillance Branch (AFHSB) website (URL: http://www.health.mil/afhsb). Personnel with recommendations to change, add, or delete from the list can contact their respective Service Reportable Medical Events/DRSi POC.

Disease Reporting System internet (DRSi) Web Links

Use your corresponding Service DRSi when reporting cases.

<table>
<thead>
<tr>
<th>Service</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Army</td>
<td><a href="https://drsi.health.mil/adrsi/">https://drsi.health.mil/adrsi/</a></td>
</tr>
<tr>
<td>Navy</td>
<td><a href="https://drsi.health.mil/ndrsi/">https://drsi.health.mil/ndrsi/</a></td>
</tr>
</tbody>
</table>
Amebiasis (*Entamoeba histolytica*)

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th><em>Entamoeba histolytica</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Present worldwide; particularly in parts of Africa, Asia, and Central and South America</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>An illness caused by infection of the large intestine that is characterized by symptoms ranging from mild, chronic diarrhea to severe and sudden onset diarrhea containing mucus, blood, or both. Extraintestinal or invasive infections can also occur and may present as an acute abscess in the liver, lung, brain or other organs. A granulomatous lesion in the intestine may be discovered on rare occasion.</td>
</tr>
</tbody>
</table>

**Case Classification**

**Probable:**
A case that meets the clinical description as described above with any of the following:
- Microscopic identification of *E. histolytica* trophozoites with ingested red blood cells from stool or
- *E. histolytica* positive antibody without clinical evidence of extraintestinal or invasive amebiasis

**Confirmed:**
An asymptomatic case with **ALL** of the following:
- *E. histolytica* nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) and
- Epidemiologically linked to a confirmed case

**Critical Reporting Elements**
Document the anatomical site of infection.
Document relevant travel and deployment history occurring within the incubation period.

**Comments**
Microscopic test from stool reported as positive for *E. histolytica* and *E. dispar* should only be reported as probable if trophozoites with ingested red blood cells are seen.

Last update: July 2017
Anthrax (*Bacillus anthracis*)

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th><em>Bacillus anthracis</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Most common in Central and South America, sub-Saharan Africa, Central and Southwestern Asia, and Southern and Eastern Europe</td>
</tr>
</tbody>
</table>

**Clinical Description**

An acute onset illness with at least one of the following:
- An illness with at least one specific OR two non-specific symptoms and signs that are compatible with cutaneous, ingestion, inhalation, or injection anthrax; systemic involvement; or anthrax meningitis or
- A death of unknown cause AND organ involvement consistent with anthrax

There are several distinct clinical forms including:
- **Cutaneous**: A painless skin lesion evolving during a period of 2-6 days from a papule, through a vesicular stage, to a depressed black eschar surrounded by edema. Fever, malaise, and lymphadenopathy may also be present.
- **Inhalation**: Symptoms resembling a viral respiratory illness, followed by hypoxia, dyspnea, or acute respiratory distress with resulting cyanosis and shock. Radiographic evidence of mediastinal widening or pleural effusion is common in later stages of illness.
- **Injection**: Severe soft tissue infection that appears like a significant edema or bruising after an injection. No eschar or pain is associated. Symptoms may also include fever, shortness of breath, or nausea.
- **Ingestion**: Presents as two subtypes
  - **Gastrointestinal**: Severe abdominal pain and tenderness, nausea, vomiting or vomiting of blood, bloody diarrhea, fever, abdominal swelling, loss of appetite, and possibly septicemia.
  - **Oropharyngeal**: A painless mucosal lesion in the oral cavity or oropharynx with pharyngitis, swollen lymph nodes in the neck, edema, fever, and possibly septicemia.
- **Meningeal**: May complicate any form of anthrax or may be a primary manifestation. Symptoms include fever, headache (often severe), nausea, vomiting, fatigue, meningeal signs, altered mental status, and other neurological signs such as seizures or focal signs are usually present. Most patients with anthrax meningitis have cerebral spinal fluid abnormalities consistent with bacterial meningitis.

**Case Classification**

**Suspect:**
A case that meets the clinical description as described above, where a test has been ordered but results are not available yet, and there is no epidemiologic evidence* of anthrax

**Probable:**
A case that meets the clinical description as described above with any of the following:
• Epidemiologically linked to a documented anthrax environmental exposure or
• Gram stain demonstrating Gram-positive rods, square-ended, in pairs or short chains or
• Positive result on a test with established performance in a CLIA-accredited laboratory

**Confirmed:**
A case that meets the clinical description as described above with any of the following:
• *B. anthracis* identified by culture by an LRN reference laboratory from any clinical specimen or
• Histopathologic identification of *B. anthracis* antigen by IHC from tissue samples using both *B. anthracis* cell wall and capsule monoclonal antibodies or
• At least a four-fold increase of *B. anthracis* IgG antibodies against protective antigen between paired acute and convalescent sera using CDC’s quantitative anti-PA IgG ELISA test or
• At least a four-fold change (increase or decrease) of *B. anthracis* IgG antibodies against protective antigen in paired convalescent sera using CDC’s quantitative anti-PA IgG ELISA test or
• Detection of lethal factor (LF) in clinical serum specimens by LF mass spectrometry or
• *B. anthracis* nucleic acid (DNA) detected by LRN-validated PCR, BioFire’s JBAIDS Anthrax Detection Kit for PX01 and PX02, or other DoD approved test from a normally sterile site (example: blood or CSF or, less commonly, joint, pleural, or pericardial fluid) or a lesion of affected tissue

**Critical Reporting Elements**
Specify the clinical form(s) of the disease.
Document the anatomical site of infection.
Document the source of infection if known.
Note the patient’s anthrax immunization history.

**Comments**
*Epidemiologic linkage includes:
• Exposure to environment, food, animal, materials, or objects that is suspect or confirmed to be contaminated with *B. anthracis*;
• Exposure to the same environment, food, animal, materials, or objects as another person who has laboratory-confirmed anthrax;
• Consumption of the same food as another person who has laboratory-confirmed anthrax.
Arboviral Diseases, Neuroinvasive and Non-neuroinvasive

INCLUDES: West Nile fever, West Nile encephalitis, Japanese encephalitis, and other mosquito-borne viruses (western equine encephalitis, eastern equine encephalitis, St. Louis encephalitis, California virus encephalitis), tick-borne viruses (Powassan virus, tick-born encephalitis, Colorado tick fever), and others.

EXCLUDES: chikungunya virus, dengue virus, Lyme disease, relapsing fever, Rift Valley fever, spotted fever rickettsiosis, yellow fever virus, and Zika virus. See respective case definitions.

Background

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>Various Arboviruses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Present worldwide</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>An illness that ranges from mild febrile illness to severe encephalitis categorized into two clinical presentations:</td>
</tr>
</tbody>
</table>

**Non-neuroinvasive disease:**
- Fever (chills) as reported by the patient or a health-care provider **AND**
- Absence of neuroinvasive disease **AND**
- Absence of a more likely clinical explanation. Other clinically compatible symptoms of arbovirus disease include: headache, myalgia, rash, arthralgia, vertigo, vomiting, paresis and/or nuchal rigidity

**Neuroinvasive disease:**
- Meningitis, encephalitis, acute flaccid paralysis, or other acute signs of central or peripheral neurologic dysfunction, as documented by a physician **AND**
- Absence of a more likely clinical explanation. Other clinically compatible symptoms of arbovirus disease include: headache, myalgia, rash, arthralgia, vertigo, vomiting, paresis and/or nuchal rigidity

Case Classification

**Non-neuroinvasive disease:**

**Probable:**
A case that meets the clinical description of non-neuroinvasive disease as described above with virus-specific positive IgM antibody from serum and no other laboratory test performed

**Confirmed:**
A case that meets the clinical description of non-neuroinvasive disease as described above with any of the following:
- Virus identified by culture from any clinical specimen except CSF or
- Virus-specific positive antigen from any clinical specimen except CSF or
- Virus-specific nucleic acid (RNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen except CSF or
- At least a four-fold change (increase or decrease) of virus-specific antibody titers between paired acute and convalescent sera or
• Virus-specific positive IgM antibody from serum followed by confirmatory virus-specific positive neutralizing antibody (example: PRNT, ELISA) in the same or a later serum specimen

**Neuroinvasive disease:**

**Probable:**
A case that meets the clinical description of neuroinvasive disease as described above with virus-specific positive IgM antibody from CSF or serum and no other laboratory test performed

**Confirmed:**
A case that meets the clinical description as described above with any of the following:

- Virus identified by culture from any clinical specimen or
- Virus-specific positive antigen from any clinical specimen or
- Virus-specific nucleic acid (RNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen or
- At least a four-fold change (increase or decrease) of virus-specific antibody titers between paired acute and convalescent sera or
- Virus-specific positive IgM antibody followed by confirmatory virus-specific positive neutralizing antibody (example: PRNT, ELISA) from serum in the same or a later specimen or
- Virus-specific positive IgM antibody from CSF and a negative IgM antibody in CSF for other arboviruses endemic to the region where exposure occurred

**Critical Reporting Elements**

Specify the etiologic/causative agent.
Document relevant travel and deployment history occurring within the incubation period.
Document the circumstances under which the case patient was exposed including duty exposure, occupational activities, environmental exposures, or other high risk activities.
Note the patient’s disease specific immunization history.

**Comments**

None.
Babesiosis (Babesia species)

**Background**

**Causative Agent** Babesia species (i.e., Babesia microti, B. duncani, B. venatorum, B. divergens-like parasites, and others)

**Travel Risks** Most commonly found in the United States (especially in the northeast and Midwest), and in parts of Europe

**Clinical Description** A parasitic disease transmitted through the bites of infected ticks or through contaminated blood components from asymptomatic parasitemic donors, or, more rarely, transplacentally. Babesia has two clinical criteria categories:
- **Measured**: Fever, anemia, or low platelet count
- **Subjective**: Chills, sweats, headache, myalgia, or arthralgia

**Case Classification**

**Suspect:** A case with any of the following:
- Microscopic identification of Babesia organisms inside red blood cells by light microscopy in a Giemsa, Wright, or Wright-Giemsa-stained blood smear or
- Babesia microti nucleic acid (DNA) identified (example: PCR, sequencing, NAAT) in a whole blood specimen or
- Any Babesia species identified by genomic sequencing in a whole blood specimen or
- Any Babesia species identified by culture from animal inoculation of whole blood or
- Babesia microti positive total antibody or positive IgG antibody titer greater than or equal to 1:256 by IFA or
- Babesia microti positive total antibody or positive IgG antibody titer greater than or equal to 1:64 by IFA if identified in epidemiologically linked blood donor/recipient Babesia microti positive IgG antibody by immunoblot (example: Western blot) or
- Babesia divergens positive total antibody or positive IgG antibody titer greater than or equal to 1:256 by IFA or
- Babesia duncani positive total antibody or positive IgG antibody titer greater than or equal to 1:512 by IFA

**Probable:** A case that meets at least one symptom in the measured clinical criteria category as described above with any of the following:
- Babesia microti positive total antibody or positive IgG antibody titer greater than or equal to 1:256 by IFA or
- Babesia microti positive total antibody or positive IgG antibody titer greater than or equal to 1:64 by IFA if identified in epidemiologically linked blood donor/recipient Babesia microti positive IgG antibody by immunoblot (example: Western blot) or
- Babesia divergens positive total antibody or positive IgG antibody titer greater than or equal to 1:256 by IFA or
- Babesia duncani positive total antibody or positive IgG antibody titer greater than or equal to 1:512 by IFA
A blood donor or recipient that is epidemiologically linked to a confirmed or probable babesiosis case with any of the following:

- Microscopic identification of *Babesia* organisms inside red blood cells by light microscopy in a Giemsa, Wright, or Wright-Giemsa-stained blood smear or
- *Babesia microti* nucleic acid (DNA) identified (example: PCR, sequencing, NAAT) in a whole blood specimen or
- Any *Babesia* species identified by genomic sequencing in a whole blood specimen or
- Any *Babesia* species identified by culture from a whole blood specimen by animal inoculation or
- *Babesia microti* positive total antibody or positive IgG antibody titer greater than or equal to 1:256 by IFA or
- *Babesia microti* positive total antibody or positive IgG antibody titer greater than or equal to 1:64 by IFA if identified in epidemiologically linked blood donor/recipient *Babesia microti* positive IgG antibody by immunoblot (example: Western blot) or
- *Babesia divergens* positive total antibody or positive IgG antibody titer greater than or equal to 1:256 by IFA or
- *Babesia duncani* positive total antibody or positive IgG antibody titer greater than or equal to 1:512 by IFA

**Confirmed:**
A case with any symptom in the measured or subjective clinical criteria as described above with any of the following:

- Microscopic identification of *Babesia* organisms inside red blood cells by light microscopy in a Giemsa, Wright, or Wright-Giemsa-stained blood smear or
- *Babesia microti* nucleic acid (DNA) identified (example: PCR, sequencing, NAAT) in a whole blood specimen or
- Any *Babesia* species identified by genomic sequencing in a whole blood specimen or
- Any *Babesia* species identified by culture from a whole blood specimen by animal inoculation

**Critical Reporting Elements**
Document potential occupational/high risk exposure during the incubation period (1-3 weeks for tick-borne disease transmission and >1 year for transfusion-associated transmission cases). High exposure activities include but are not limited to outdoor activity, camping, hunting, field exercise, mission/duty related, etc.
Document if the source is tick-borne or transfusion-associated.
Document the circumstances under which the case patient was exposed including duty exposure, occupational activities, environmental exposures, or other high risk activities.

**Comments**
Epidemiologic linkage between a blood transfusion recipient and donor is demonstrated if all of the below criteria are met:

- In the transfusion recipient, all of the following:
  - Received one or more red blood cell (RBC) or platelet transfusions within one year before the collection date of a specimen with laboratory evidence of *Babesia* infection and
- At least one of these transfused blood components was donated by the donor described below and
- Transfusion-associated infection is considered at least as plausible as tick-borne transmission

- In the blood donor, all of the following:
  - Donated at least one of the RBC or platelet components that was transfused into the above recipient and
  - The plausibility that this blood component was the source of infection in the recipient is considered equal to or greater than that of blood from other involved donors (more than one plausible donor may be linked to the same recipient).
Botulism (*Clostridium botulinum* toxin)

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th><em>Clostridium botulinum</em> toxin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>N/A</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>Botulism is categorized into four clinical manifestations:</td>
</tr>
<tr>
<td></td>
<td><strong>Foodborne:</strong> An illness of variable severity. Common symptoms are diplopia, blurred vision, and bulbar weakness. Symmetric paralysis may progress rapidly.</td>
</tr>
<tr>
<td></td>
<td><strong>Infant:</strong> An illness of infants aged less than 1 year, characterized by constipation, poor feeding, and “failure to thrive” that may be followed by progressive weakness, impaired respiration, and death.</td>
</tr>
<tr>
<td></td>
<td><strong>Wound:</strong> An illness resulting from toxin produced by <em>Clostridium botulinum</em> that has infected a wound. Common symptoms are diplopia, blurred vision, and bulbar weakness. Symmetric paralysis may progress rapidly.</td>
</tr>
<tr>
<td></td>
<td><strong>Other:</strong> An illness of variable severity that occurs among persons greater than 1 year of age. Common symptoms are diplopia, blurred vision, and bulbar weakness. Symmetric paralysis may progress rapidly.</td>
</tr>
</tbody>
</table>

**Case Classification**

**Foodborne:**

Probable:
A case that meets the clinical description of foodborne botulism as described above that is epidemiologically linked to a food source (example: ingestion of a home-canned food within the previous 48 hours)

Confirmed:
A case that meets the clinical description of foodborne botulism as described above with any of the following:

- A history of eating the same food as a laboratory confirmed case or
- *C. botulinum* toxin detected in serum, stool, or patient’s food or
- Toxin producing *C. botulinum* identified by culture from stool

**Infant:**

Confirmed:
A case that meets the clinical description of infant botulism as described above with any of the following:

- *C. botulinum* toxin detected in serum or stool or
- Toxin producing *C. botulinum* identified by culture from stool

**Wound:**

Probable:
A case that meets clinical description of wound botulism as described above in a patient who has no suspected exposure to contaminated food and who has any of the following:

- A history of a fresh, contaminated wound during the 2 weeks before onset of symptoms or
• A history of injection drug use within the 2 weeks before onset of symptoms

Confirmed:
A case that meets **ALL** of the following:
• Meets the clinical description of wound botulism as described above in a patient who has no suspected exposure to contaminated food and who has any of the following exposures:
  o A history of a fresh, contaminated wound during the 2 weeks before onset of symptoms
  o A history of injection drug use within the 2 weeks before onset of symptoms
• Any of the following:
  o *C. botulinum* toxin detected in serum
  o Toxin producing *C. botulinum* identified by culture from a wound

Other:
Confirmed:
A case that meets the clinical description of other botulism as described above without a history of ingestion of suspect food and has no wounds, and who has any of the following:
• *C. botulinum* toxin detected in any clinical specimen
• Toxin producing *C. botulinum* identified by culture from any clinical specimen

**Critical Reporting Elements**
Specify the clinical form of the disease.
Document the source of infection if known.

**Comments**
None.

Last update: July 2017
Brucellosis (*Brucella* species)

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th><em>Brucella</em> species</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Present worldwide</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>An acute systemic disease characterized by fever plus any of the following: night sweats, arthralgia, headache, fatigue, anorexia, myalgia, weight loss, arthritis, spondylitis, meningitis, or focal organ involvement (endocarditis, orchitis, epididymitis, hepatomegaly, splenomegaly).</td>
</tr>
</tbody>
</table>

**Case Classification**

**Probable:**
A case that meets the clinical description as described above with any of the following:
- Epidemiologically linked to a confirmed human or animal case or
- *Brucella* total antibody titer ≥ 1:160 by SAT or MAT from serum or
- *Brucella* nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen

**Confirmed:**
A case that meets the clinical description as described above with any of the following:
- *Brucella* identified by culture from any clinical specimen or
- At least a four-fold increase of *Brucella* antibody titer between paired acute and convalescent sera separated by at least 2 weeks

**Critical Reporting Elements**
Document relevant travel and deployment history occurring within the incubation period.
Document the source of infection if known.
Document the circumstances under which the case patient was exposed including duty exposure, occupational activities, environmental exposures, or other high risk activities.

**Comments**
A positive *Brucella* slide agglutination test is the same thing as MAT; it therefore meets the probable case definition and should be reported.

Last update: July 2017
**Campylobacteriosis (Campylobacter species)**

### Background

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>Campylobacter species</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Present worldwide</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>An acute enteric disease characterized by diarrhea, abdominal pain, nausea, and sometimes vomiting. Severe symptoms and invasive infections occur rarely causing bacteremia, meningitis or other focal infections.</td>
</tr>
</tbody>
</table>

### Case Classification

**Probable:**

- Any of the following:
  - *Campylobacter* positive laboratory test by a method other than culture (example: EIA, PCR) from any clinical specimen or
  - A case that meets the clinical description as described above that is epidemiologically linked to a probable or a confirmed case

**Confirmed:**

*Campylobacter* identified by culture from any clinical specimen

### Critical Reporting Elements

- Document the species if known.
- Document the source of infection if known.
- Document relevant travel and deployment history occurring within the incubation period.
- Document the circumstances under which the case patient was exposed including duty exposure, occupational activities, environmental exposures, or other high risk activities.
- Document if the case patient works in, lives in, or attends a high transmission setting such as food handling, day care, school, group living, healthcare, training center, or ship.

### Comments

None.

Last update: July 2017
# Chikungunya Virus Disease (chikungunya virus)

## Background

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>chikungunya virus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Most common in Africa, Asia, parts of Central and South America, islands in the Indian Ocean, Western and South Pacific, and Caribbean</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>Chikungunya typically causes non-neuroinvasive symptoms causing high fever (typically &gt; 102°F [&gt; 39°C]), severe arthralgia, arthritis, rash, headache, conjunctivitis, nausea, vomiting, and lymphopenia. Joint symptoms are usually bilateral and symmetric, and can be severe and debilitating. Acute symptoms typically resolve within 7 to 10 days.</td>
</tr>
</tbody>
</table>

## Case Classification

### Probable:

A case that meets the clinical description as described above with **ALL** of the following:

- Chikungunya positive IgM antibody from CSF or serum and
- No other laboratory test performed

### Confirmed:

A case that meets the clinical description as described above with any of the following:

- Chikungunya identified by culture from tissue, blood, CSF, or other body fluid or
- Chikungunya positive antigen from tissue, blood, CSF, or other body fluid or
- Chikungunya nucleic acid (RNA) detected (example: PCR, sequencing, NAAT) from tissue, blood, CSF, or other body fluid or
- At least a four-fold change (increase or decrease) of antibody titer between paired acute and convalescent sera or
- Chikungunya positive IgM antibodies from serum followed by confirmatory virus-specific neutralizing antibodies (example: PRNT, ELISA) in the same or a later specimen

## Critical Reporting Elements

Document relevant travel and deployment history occurring within the incubation period.

Document the circumstances under which the case patient was exposed including duty exposure, occupational activities, environmental exposures, or other high risk activities.

## Comments

None.

Last update: July 2017
**Chlamydia Infection (Chlamydia trachomatis)**

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>Chlamydia trachomatis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>N/A</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>An infection characterized by urethritis, epididymitis, cervicitis, acute salpingitis, or other syndromes when sexually transmitted. Infections are often asymptomatic in women. Perinatal infections may result in inclusion conjunctivitis and pneumonia in newborns. Other syndromes caused by C. trachomatis include lymphogranuloma venereum and trachoma.</td>
</tr>
</tbody>
</table>

**Case Classification**

**Confirmed:**
A case with any of the following:

- *C. trachomatis* identified by culture from any clinical specimen or
- *C. trachomatis* positive antigen from any clinical specimen or
- *C. trachomatis* nucleic acid (DNA) detected (example: PCR, sequencing, NAAT, probe) from any clinical specimen

**Critical Reporting Elements**

None.

**Comments**

Report co-infections with other organisms, like gonorrhea, separately as individual RMEs.

Last update: July 2017
## Cholera (Cholera Toxin-Producing Vibrio cholerae O1 or O139)

### Background
<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>Cholera toxin-producing Vibrio cholerae, serogroup O1 or O139</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Present worldwide; particularly in sub-Saharan Africa, the Indian Subcontinent, and Southeast Asia</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>An acute illness characterized by profuse watery diarrhea and vomiting. Severity is variable; however, severe cases can result in rapid dehydration, electrolyte disturbances, and death.</td>
</tr>
</tbody>
</table>

### Case Classification
**Confirmed:**
A case that meets the clinical description as described above with any of the following:
- Cholera toxin producing *V. cholerae* O1 or O139 identified by culture from stool or vomitus or
- Cholera toxin-producing *V. cholerae* O1 or O139 positive antibody (anti-toxin antibody or vibriocidal antibody) from serum or
- Cholera toxin-producing *V. cholerae* O1 or O139 nucleic acid (DNA) detected (example: PCR, sequencing, NAAT, probe) from stool or vomitus

### Critical Reporting Elements
Specify the serogroup (*V. cholerae* O1 or *V. cholerae* O139) if known.
Document relevant travel and deployment history occurring within the incubation period.

### Comments
Not all *V. cholerae* O1 or O139 is reportable. Only *V. cholerae* O1 or O139 that produces cholera toxin is reportable.
Coccidioidomycosis (*Coccidioides* species)

COMMON NAME: valley fever

EXCLUDES: Rift Valley fever. See Rift Valley fever case definition.

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th><em>Coccidioides</em> species</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Most common in Southwest United States, Mexico, Central and South America</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>An illness characterized with at least one of the following: Influenza-like symptoms (example: fever, chest pain, cough, myalgia, arthralgia, and headache), pneumonia or pulmonary lesion, erythema nodosum or multiforme rash, involvement of bones, joints, or skin by dissemination, meningitis or involvement of the viscera and lymph nodes. Infection may disseminate to multiple organ systems.</td>
</tr>
</tbody>
</table>

**Case Classification**

Confirmed:

A case that meets the clinical description as described above with any of the following:

- Coccidioidal positive IgM antibody by immunodiffusion, EIA, latex agglutination, or tube precipitin from any bodily fluid or
- Coccidioidal positive IgG antibody by EIA or complement fixation from any bodily fluid or
- *Coccidioides* identified by culture from any clinical specimen or
- Histopathologic identification of *Coccidioides* antigen by IHC from tissue samples or
- Coccidioidal skin-test conversion from negative to positive after onset of clinical signs and symptoms

**Critical Reporting Elements**

Document the source of infection if known.

Document any relevant travel and deployment history within the incubation period.

**Comments**

None.
Cold Weather Injuries

INCLUDES: Service Member cases only

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>N/A</td>
</tr>
<tr>
<td>Clinical Description</td>
<td><strong>Hypothermia:</strong> Reduction of body temperature to ≤ 95°F. It can result from either dry-land whole body exposure to cold temperatures or immersion in cold water. Freezing temperatures are not required to produce hypothermia.</td>
</tr>
</tbody>
</table>

**Freezing Peripheral Injuries:** Freezing injuries (example: frostbite) occur only when exposed to temperatures below freezing. They result from the freezing of tissue fluids in the skin and/or subcutaneous tissues. Although it has often been classified as 1st to 4th degree levels of injury severity, final classification often takes weeks and is not helpful for immediate treatment. A more recent classification system uses two levels: superficial or deep injuries. Do not delay reporting to determine classification.

**Non-Freezing Peripheral Injuries:** A spectrum of localized non-freezing injuries, usually of extremities (example: trench foot, immersion foot, chilblains), that occur due to prolonged vasoconstriction in response to cold that leads to tissue injury and destruction. These injuries develop over a period of hours to days. They may occur at temperatures below or above freezing and can occur at temperatures as high as 60°F with prolonged exposure. Injury is accelerated by exposure to damp conditions. (Note: The term “trench foot” is also sometimes used to describe a tropical foot injury or “jungle rot.”)

**Case Classification**

**Hypothermia:**

**Probable:** A case of provider-diagnosed hypothermia

**Confirmed:** A case that meets the clinical description of hypothermia as described above with a core body temperature ≤ 95°F or ≤ 35°C as measured by rectal, esophageal, or other central method

**Freezing Peripheral Injuries:**

**Confirmed:** A case that meets the clinical description of freezing peripheral injuries as described above occurring from exposure to temperatures below freezing where the extent of the freezing injury can be classified as:

- **Superficial:** Partial or full thickness freezing of the epidermis without involvement of the underlying tissue. Mobility is unaffected, and blistering may occur or
- **Deep:** Full thickness freezing of the epidermis accompanied by freezing of subcutaneous tissue and which may involve muscles, tendons, and bones as severity increases or
- **Unknown:** As yet unclassified
Non-Freezing Peripheral Injuries:

Confirmed:
A case that meets the clinical description of non-freezing peripheral injuries as described above occurring from exposure to a cold and wet or damp environment.

Critical Reporting Elements
Specify the type of injury.
Document the anatomical site of injury.
Document the circumstances under which the case patient was exposed including duty exposure, occupational activities, environmental exposures, or other high risk activities.

Comments
Please specify ambient temperature if known in degrees Fahrenheit (estimate if unknown).
COVID-19 Associated Hospitalization and Death (SARS coronavirus-2)

INCLUDES: Hospitalized cases and deaths caused by SARS-CoV-2

EXCLUDES: Non-hospitalized COVID-19 cases and seasonal (non-pandemic) coronavirus (CoV-NL63, CoV-229E, CoV-OC43, and CoV-HKU1, etc.) cases; asymptomatic COVID-19 cases; hospitalizations for reasons other than COVID-19 (even with a positive test)

**Background**

**Causative Agent**

Coronavirus Disease 2019, SARS-CoV-2

**Travel Risks**

Present worldwide

**Clinical Description**

An illness with acute onset or worsening of any cough; shortness of breath; difficulty breathing; olfactory disorder; taste disorder; confusion or change in mental status; persistent pain or pressure in the chest; pale, grey, or blue-colored skin, lips, or nail beds (depending on skin tone); inability to wake or stay awake; clinical radiographic evidence of pneumonia; or acute respiratory distress syndrome (ARDS)

**Case Classification**

**Probable:**

A hospitalized case or death that meets the clinical description as described above with any of the following:

- SARS-CoV-2 positive antigen (example: EIA, ELISA) from any clinical specimen or
- A death certificate that lists COVID-19 disease, SARS-CoV-2, or an equivalent term as an underlying cause of death or a significant condition contributing to death

**Confirmed:**

A hospitalized case or death that meets the clinical description as described above where SARS-CoV-2 nucleic acid (RNA) was detected (example: PCR, sequencing, NAAT) from any clinical specimen

**Critical Reporting Elements**

Document if the patient was hospitalized, including admission and discharge dates, place of hospital admission, and clinical course.

Document if the patient died, including the date of death.

Document if the patient works in, lives in, or attends a high transmission setting such as, day care, school, group living, healthcare, training center, or ship.

Document if the patient has any relevant comorbidities, underlying illnesses, or is otherwise immunocompromised (e.g., via immunocompromising medications).

Document if the patient was vaccinated for SARS-CoV-2, vaccine manufacturer, and date(s) of vaccination.

Specify the variant if known.
Comments

Hospitalization is defined as an admission to an inpatient ward of a hospital, or a medical transfer, or evacuation to a facility with a higher level of care. Patients admitted for observation and discharged the same day are considered hospitalized for this case definition. An overnight stay is not required. Emergency room or outpatient clinic visits that do not result in hospital admission are not considered hospitalizations.

Cases that are hospitalized for other reasons (e.g., child birth, surgery) with an incidental COVID-19 positive test do not meet this case definition and, therefore, are not reportable.
Cryptosporidiosis (*Cryptosporidium* species)

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th><em>Cryptosporidium</em> species</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>N/A</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>An illness characterized by diarrhea and any of the following: duration of diarrhea of 72 hours or more, abdominal cramping, vomiting, or anorexia.</td>
</tr>
</tbody>
</table>

**Case Classification**

**Probable:**
A case with any of the following:
- *Cryptosporidium* positive antigen by a screening test (example: immunochromatographic lateral flow test, rapid card test) or
- *Cryptosporidium* positive laboratory test of unknown method or
- A case that meets the clinical description as described above that is epidemiologically linked to a confirmed case

**Confirmed:**
A case with any of the following:
- *Cryptosporidium* positive antigen by EIA or DFA from any clinical specimen or
- *Cryptosporidium* nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen or
- Microscopic identification of *Cryptosporidium* from any clinical specimen

**Critical Reporting Elements**
Document the source of infection if known.
Document the circumstances under which the case patient was exposed including duty exposure, occupational activities, environmental exposures, or other high risk activities.
Document if the case patient works in, lives in, or attends a high transmission setting such as food handling, day care, school, group living, healthcare, training center, or ship.

**Comments**
None.

Last update: July 2017
# Cyclosporiasis (*Cyclospora cayetanensis*)

## Background

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th><em>Cyclospora cayetanensis</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Most common in tropical or subtropical regions</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>The most common symptom is watery diarrhea with frequent bowel movements. Other common symptoms include loss of appetite, weight loss, abdominal cramps/bloating, nausea, body aches, and fatigue. Vomiting and low-grade fever also may be noted.</td>
</tr>
</tbody>
</table>

## Case Classification

**Probable:**
A case that meets the clinical description as described above that is epidemiologically linked to a confirmed case

**Confirmed:**
A case that meets the clinical description as described above with any of the following:

- *C. cayetanensis* nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from stool, intestinal fluid/aspirate or intestinal biopsy specimens or
- Microscopic identification of *C. cayetanensis* from stool, intestinal fluid/aspirate or intestinal biopsy specimens

## Critical Reporting Elements

Document the source of the infection if known.
Document if the case patient works in, lives in, or attends a high transmission setting such as food handling, day care, school, group living, healthcare, training center, or ship.

## Comments

None.
Dengue Virus Infection (dengue virus -1, -2, -3, and -4)

Background
Causative Agent dengue virus (DENV-1, -2, -3, and -4)
Travel Risks Most common in tropical and subtropical areas of South America, Africa and Asia, Mexico, and Oceana to include the Pacific and the Caribbean
Clinical Description An acute febrile illness typically presenting with at least one of the following: nausea, vomiting, rash, aches and pains, tourniquet test positive or leukopenia. Severe manifestations (severe plasma leakage, severe bleeding from the gastrointestinal tract or vagina, or severe organ involvement) are rare, but may be fatal.

Case Classification
Probable:
A case that meets the clinical description as described above with:
- Dengue positive IgM antibody from serum or CSF in a person who has:
  - Documented or unknown exposure to other flaviviruses (example: Yellow Fever virus, Japanese encephalitis virus, West Nile virus) or
  - Recent receipt of a flavivirus vaccine

Confirmed:
A case that meets the clinical description as described above with any of the following:
- Dengue nucleic acid (RNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen or
- Dengue positive antigen by DFA or IFA from tissue or
- Histopathologic identification of dengue antigen by IHC from tissue
- Dengue NS1 positive antigen from serum or plasma or
- Dengue identified by culture from a serum, plasma, or CSF or
- Dengue positive IgM antibody from serum or CSF in a person who has had no documented exposure to other flaviviruses (example: Yellow Fever virus, Japanese encephalitis virus, West Nile virus) or recent receipt of a flavivirus vaccine or
- Seroconversion from a negative IgM in an acute sera collected < 5 days after illness onset followed by a positive IgM in convalescent sera collected > 5 days after illness onset or
- Seroconversion from a negative IgG followed by a positive IgG in samples separated by at least 2 weeks or
- At least a four-fold increase of antibody titer between paired acute and convalescent sera separated by at least 2 weeks followed by a confirmatory neutralization test (example: PRNT, ELISA) that has a greater than four-fold higher end point titer as compared to the other flaviviruses tested with it

Critical Reporting Elements
Specify serotype if known.
Document relevant travel and deployment history occurring within the incubation period.

Comments
None.

Last update: July 2017
Diphtheria (*Corynebacterium diphtheriae*)

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th><em>Corynebacterium diphtheriae</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Present worldwide; particularly tropical areas</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>This disease primarily manifests as respiratory infections that may result in death, but it may also present as mild infections in non-respiratory sites, such as the skin. A case of diphtheria may present as:</td>
</tr>
<tr>
<td></td>
<td>• Respiratory: Upper respiratory tract illness with an adherent membrane of the nose, pharynx, tonsils, or larynx or</td>
</tr>
<tr>
<td></td>
<td>• Non-respiratory: Infection of a non-respiratory anatomical site (e.g., skin, wound, conjunctiva, ear, genital mucosa)</td>
</tr>
</tbody>
</table>

**Case Classification**

**Suspect:**

In the absence of a more likely diagnosis, a case that meets the respiratory clinical description as described above with **ALL** of the following:

- No laboratory confirmation and
- Not epidemiologically linked to a laboratory-confirmed case of diphtheria

OR

Histopathologic identification of diphtheria antigen by IHC from tissue

**Confirmed:**

A case that meets the respiratory clinical description as described above with any of the following:

- Toxin-producing *C. diphtheriae* identified by culture from the nose or throat or
- Epidemiologically linked to a confirmed case

OR

A case that meets the non-respiratory clinical description as described above with:

- Toxin-producing *C. diphtheriae* identified by culture from the infection site

**Critical Reporting Elements**

Document relevant travel and deployment history occurring within the incubation period.

Note the patient’s diphtheria immunization history.

Document if the case patient works in, lives in, or attends a high transmission setting like, day care, school, group living, or healthcare.

**Comments**

A patient without evidence of clinical symptoms as described above is not considered a reportable case despite a confirmatory lab test for toxin-producing *C. diphtheriae*.
**Escherichia coli, Shiga Toxin Producing (STEC) Infection**

**COMMON NAME:** Enterohemorrhagic *E. coli* (EHEC), Verotoxin *E. coli* (VTEC)

**INCLUDES:** *E. coli* O157:H7, *E. coli* O113, *E. coli* O118, *E. coli* O111, *E. coli* O26, etc.

**EXCLUDES:** Enterotoxigenic *E. coli* (ETEC), Enteropathogenic *E. coli* (EPEC), Enteroinvasive *E. coli* (EIEC), Enteroaggregative *E. coli* (EAEC)

**Background**

**Causative Agent** *Escherichia coli*, Shiga toxin producing

**Travel Risks** Most common in North America, Europe, Japan, the southern cone of South America, and Southern Africa

**Clinical Description** An infection of variable severity characterized by diarrhea (often bloody) and abdominal cramps. The illness may be complicated by hemolytic uremic syndrome (HUS) or thrombotic thrombocytopenic purpura (TTP). HUS is characterized by the acute onset of microangiopathic hemolytic anemia, renal injury, and low platelet count. TTP also is characterized by these features but can include central nervous system (CNS) involvement and fever and may have a more gradual onset. Most cases of HUS (but few cases of TTP) occur after an acute gastrointestinal illness (usually diarrheal). The organism rarely causes extraintestinal infections.

**Case Classification**

**Suspect:** A case with any of the following:
- A diagnosis of post-diarrheal HUS/TTP or
- A case with no known clinical information available and any of the following:
  - An elevated antibody titer against a known STEC serotype from serum or
  - Shiga toxin or Shiga toxin genes detected by a method other than culture (example: PCR, EIA) from any clinical specimen and no known *Shigella* culture or
  - *E. coli* O157 or other STEC identified by a method other than culture (example: PCR, EIA) from any clinical specimen

**Probable:** A case with any of the following:
- *E. coli* O157 identified by culture from any clinical specimen without confirmation of H antigen, or without detection of Shiga toxin, or Shiga toxin genes or
- A case that meets the clinical description as described above and any of the following:
  - An elevated antibody titer against a known STEC serotype from serum or
  - Shiga toxin or Shiga toxin genes detected by a method other than culture (example: PCR, EIA) from any clinical specimen and no known *Shigella* culture or
  - *E. coli* O157 or other STEC identified by a method other than culture (example: PCR, EIA) or
  - Epidemiologically linked to a confirmed or probable case with laboratory evidence
**Confirmed:**
A case with any of the following:
- *E. coli* O157 identified by culture from any clinical specimen or
- *E. coli* identified by culture with detection of Shiga toxin or Shiga toxin genes

**Critical Reporting Elements**
Document if the case patient works in, lives in, or attends a high transmission setting such as food handling, day care, school, group living, healthcare, training center, or ship.
Document the source of infection if known.
Document relevant travel and deployment history occurring within the incubation period.

**Comments**
*Shigella* also produces Shiga toxin. Persons with (1) detection of Shiga toxin or Shiga toxin genes using a test other than culture and (2) a positive culture of *Shigella* from any clinical specimen should not be reported as an STEC case, but should be reported as *Shigella*.
Ehrlichiosis and Anaplasmosis (*Anaplasma phagocytophilum, Ehrlichia chaffeensis, Ehrlichia ewingii*)

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>Anaplasma phagocytophilum, Ehrlichia chaffeensis, Ehrlichia ewingii</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Southeastern and south-central United States, Europe, Asia</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>A tick borne illnesses characterized by fever plus one or more of the following: headache, myalgia, malaise, anemia, leukopenia, thrombocytopenia, or elevated hepatic transaminases.</td>
</tr>
</tbody>
</table>

**Case Classification**

**A. phagocytophilum or E. chaffeensis:**

**Suspect:**
A case with any of the following:
- *A. phagocytophilum* or *E. chaffeensis* nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen or
- Histopathologic identification of anaplasmal or ehrlichial antigen by IHC from a biopsy or autopsy tissue sample or
- *A. phagocytophilum* or *E. chaffeensis* identified by culture from any clinical specimen or
- *A. phagocytophilum* or *E. chaffeensis* positive IgG or IgM antibody (example: IFA or ELISA) from serum

**Probable:**
A case that meets the clinical description as described above with any of the following:
- *A. phagocytophilum* or *E. chaffeensis* positive IgG or IgM antibody (example: IFA or ELISA) from serum or
- Microscopic identification of morulae in the cytoplasm of neutrophils or eosinophils

**Confirmed:**
A case that meets the clinical description as described above with any of the following:
- At least a four-fold change (increase or decrease) of IgG antibody titer against *A. phagocytophilum* or *E. chaffeensis* antigen by IFA between paired acute and convalescent sera (the acute sample taken in the first week of illness and the second sample taken 2 – 4 weeks later) or
- *A. phagocytophilum* or *E. chaffeensis* nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen or
- Histopathologic identification of anaplasmal or ehrlichial antigen by IHC from a biopsy or autopsy tissue or
- *A. phagocytophilum* or *E. chaffeensis* identified by culture from any clinical specimen

**E. ewingii:**

**Suspect:**
A case with *E. ewingii* nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen

**Confirmed:**
A case that meets the clinical description as described above with *E. ewingii* nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen

**Undetermined ehrlichiosis or anaplasmosis:**

**Probable:**
A case that meets the clinical description as described above with identification of morulae in the cytoplasm of monocytes, macrophages, neutrophils, or eosinophils by microscopic examination

**Critical Reporting Elements**
Document relevant travel and deployment history occurring within the incubation period.
Document the circumstances under which the case patient was exposed to ticks including duty exposure, occupational activities, environmental exposures, or other high risk activities.
Specify the etiologic agent.

**Comments**
For acute and convalescent testing, the first serum should be taken in the first week of illness.
### Filariasis (*Wuchereria bancrofti, Brugia malayi, Brugia timori*), Loiasis (*Loa loa*), and Onchocerciasis (*Onchocerca volvulus*)

#### Background

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>Filariasis (<em>Wuchereria bancrofti, Brugia malayi, Brugia timori</em>), Onchocerciasis (<em>Onchocerca volvulus</em>), Loiasis (<em>Loa loa</em>), and others</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Most common in tropical and subtropical areas of Asia, Africa, the Western Pacific, and parts of South America and the Caribbean</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>Filariasis: An acute illness that may be characterized by recurrent fevers, lymphadenitis, retrograde lymphangitis (i.e., inflammation of lymph vessels), “elephantiasis”, or tropical pulmonary eosinophilia syndrome that is characterized by cough, shortness of breath, wheezing, and eosinophilia.</td>
</tr>
<tr>
<td></td>
<td>Onchocerciasis: An illness characterized by small solid nodules beneath the skin that can be felt by touch, severe pruritus, pigmentation changes, and corneal opacities potentially leading to blindness in severe infections.</td>
</tr>
<tr>
<td></td>
<td>Loiasis: An illness characterized by transient swelling and generalized pruritus, often with eosinophilia. Loiasis may also result in eye worm causing eye congestion, itching, pain, and light sensitivity.</td>
</tr>
</tbody>
</table>

#### Case Classification

**Probable:**
A case that meets the clinical description as described above with antifilarial positive IgG4 antibody from blood

**Confirmed:**
A case that meets the clinical description as described above with any of the following:
- Microscopic identification of microfilariae from blood, urine, or skin or
- Identification of the adult worm by a microbiologist or pathologist following removal from skin or eye

#### Critical Reporting Elements

Specify the etiologic/causative agent.
Document relevant travel and deployment history occurring within the incubation period.

#### Comments

None.
**Giardiasis** (*Giardia lamblia*)

### Background

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th><em>Giardia lamblia</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Present worldwide</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>An illness characterized by gastrointestinal symptoms such as diarrhea, abdominal cramps, bloating, weight loss, or malabsorption.</td>
</tr>
</tbody>
</table>

### Case Classification

**Probable:**
A case that meets the clinical description as described above that is epidemiologically linked to a confirmed case

**Confirmed:**
A case that meets the clinical description as described above with any of the following:
- Microscopic identification of *Giardia* cysts or trophozoites from any clinical specimen or
- *Giardia* positive antigen (example: EIA, DFA) from any clinical specimen or
- *Giardia* nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen

### Critical Reporting Elements

Document the circumstances under which the case patient was exposed including duty exposure, occupational activities, environmental exposures, or other high risk activities.

Document if the case patient works in, lives in, or attends a high transmission setting such as food handling, day care, school, group living, healthcare, training center, or ship.

### Comments

None.
## Gonorrhea (*Neisseria gonorrhea*)

### Background

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th><em>Neisseria gonorrhea</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>N/A</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>A sexually transmitted infection commonly manifested by urethritis, cervicitis, salpingitis, or pharyngitis.</td>
</tr>
</tbody>
</table>

### Case Classification

#### Probable:

A case with any of the following:
- Microscopic identification of gram negative intracellular diplococci in a urethral smear obtained from a male or
- Microscopic identification of gram negative intracellular diplococci in an endocervical smear obtained from a female

#### Confirmed:

A case with any of the following:
- *N. gonorrhoeae* identified by culture from any clinical specimen or
- *N. gonorrhoeae* positive antigen from any clinical specimen or
- *N. gonorrhoeae* nucleic acid (DNA) detected (example: PCR, sequencing, NAAT, probe) from any clinical specimen

### Critical Reporting Elements

None.

### Comments

Report co-infections with other organisms, like chlamydia, separately as individual RMEs.
**Haemophilus influenzae, Invasive (Haemophilus influenzae)**

**EXCLUDES:** Conjunctivitis

<table>
<thead>
<tr>
<th><strong>Background</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Causative Agent</strong></td>
</tr>
<tr>
<td><strong>Travel Risks</strong></td>
</tr>
<tr>
<td><strong>Clinical Description</strong></td>
</tr>
</tbody>
</table>

**Case Classification**

**Probable:**
A case of meningitis with *H. influenzae* type b positive antigen from CSF

**Confirmed:**
A case with any of the following:
- *H. influenzae* identified by culture from a normally sterile body site (example: CSF, blood, joint fluid, pleural fluid, pericardial fluid) or
- *H. influenzae* nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from a specimen obtained from a normally sterile body site (example: CSF, blood, joint fluid, pleural fluid, pericardial fluid)

**Critical Reporting Elements**

Note the patient’s *H. influenzae* immunization history.

**Comments**

None.

---

Last update: July 2017
### Hantavirus Disease (*Bunyaviridae* viruses)

**COMMON NAME:** Korean hemorrhagic fever, hemorrhagic fever with renal syndrome (HFRS)

#### Background

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>Region-specific hantaviruses (<em>Bunyaviridae</em>)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Most common in Western United States, Canada, South America, Central America, China, Russia, and Korea</td>
</tr>
</tbody>
</table>

**Clinical Description**

- **Hantavirus infection, non-pulmonary syndrome:** A febrile illness with non-specific viral symptoms including fever (temperature greater than 101.0°F or 38.3°C), chills, myalgia, headache, and gastrointestinal symptoms, without cardiopulmonary symptoms.

- **Hantavirus pulmonary syndrome (HPS):** A febrile illness (temperature greater than 101.0°F or 38.3°C) with chills, myalgia, and gastrointestinal symptoms and at least one of the following: bilateral diffuse interstitial edema, acute respiratory distress syndrome, noncardiogenic pulmonary edema, or physician-diagnosed HPS.

- **Hantavirus hemorrhagic fever with renal syndrome (HFRS), including Korean Hemorrhagic Fever:** An illness characterized by acute onset of fever, lower back pain, hemorrhagic manifestations and renal involvement.

#### Case Classification

**Confirmed:**

A case that meets any of the clinical descriptions as described above with any of the following:

- Hantavirus positive IgM antibody from serum or
- Hantavirus rising IgG antibody titers between acute and convalescent sera or
- Hantavirus nucleic acid (RNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen or
- Histopathologic identification of hantavirus antigen by IHC from a lung biopsy or autopsy tissues

#### Critical Reporting Elements

Specify the clinical form of the disease.

Document relevant travel and deployment history occurring within the incubation period.

Document the circumstances under which the case patient was exposed including duty exposure, occupational activities, environmental exposures, or other high risk activities.

#### Comments

None.

---

Last update: July 2017
Heat Illness

INCLUDES: Service Member cases only

EXCLUDES: Cases of simple parade syncope (heat syncope), heat edema, heat cramps, miliaria rubra, sunburn, transient heat fatigue and isolated rhabdomyolysis (i.e., without evidence for or diagnosis of a reportable heat illness). Cases of heat illness in the absence of medical intervention or change in duty status are also excluded.

Background

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>N/A</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>Heat Illness encompasses a spectrum of acute conditions associated with exertion or heat exposure.</td>
</tr>
</tbody>
</table>

**Heat Exhaustion:** Heat exhaustion (HE) is defined as the inability to continue physical activity due to competing demand for cardiac output between thermoregulation and metabolic requirements. Clinically, HE may present as weakness, fatigue, ataxia, dizziness, headache, nausea, vomiting, and malaise in individuals with a core body temperature less than 104°F or 40°C. HE may be accompanied by evidence of end organ damage (Hypo/hyperkalemia, Elevated AST or ALT, Elevated CK, Rhabdomyolysis/myoglobinuria). HE resolves rapidly with minimal cooling intervention.

**Heat Stroke:** Heat stroke (HS) is defined as an elevated core body temperature associated with central nervous system (CNS) dysfunction. Clinically, HS presents as hyperthermia, physical collapse or debilitation, and encephalopathy as evidenced by a change in mental status, delirium, stupor, or coma, occurring during or immediately following exertion or significant heat exposure. HS may be complicated by organ and/or tissue damage, systemic inflammatory activation, and disseminated intravascular coagulation. Heat stroke will likely be the working diagnosis for any service member with altered mental status and exposure history consistent with heat illness.

Case Classification

**Heat Exhaustion (HE):**

**Confirmed:**

A case that meets the clinical description of HE as described above occurring during/immediately after exertion or heat exposure with **ALL** of the following:

- Core body temperature > 100.5°F or 38°C and < 104°F or 40°C (or evidence of elevated core body temperature if cooling was initiated in the field) and
- Short-term physical collapse or debilitation occurring during or shortly after physical exertion that rapidly resolves with minimal cooling intervention and
- No evidence of CNS dysfunction or only minor CNS symptoms (e.g., headache, dizziness) that rapidly resolves with minimal cooling intervention
Heat Stroke (HS):

Probable:
A case that meets the clinical description of HS as described above occurring during/immediately after exertion or heat exposure with **ALL** of the following:
- Evidence of elevated core body temperature (even if cooling was initiated in the field) and
- CNS dysfunction (change in mental status, delirium, stupor, loss of consciousness or coma)

Confirmed:
A case that meets the clinical description as described above occurring during/immediately after exertion or heat exposure with **ALL** of the following:
- Core body temperature ≥ 104°F or 40°C and
- CNS dysfunction (change in mental status, delirium, stupor, loss of consciousness or coma)

Critical Reporting Elements
Specify the type of illness.
Document the circumstances under which the case patient was exposed including duty exposure, occupational activities, environmental exposures, or other high risk activities.

Comments
Please specify Wet Bulb Globe Temperature (WBGT) if known in degrees Fahrenheit.

Last update: July 2017
Hemorrhagic Fever, Viral (VHF)

EXCLUDES: dengue hemorrhagic fever, hantavirus hemorrhagic fever, Korean hemorrhagic fever, chikungunya, yellow fever. See each respective case definition.

Background

Causative Agents: Varies. Includes but is not limited to: Junin virus, Machupo virus, Guanarito virus, Sabia virus, Lassa virus, Lujo virus, Crimean-Congo hemorrhagic fever virus, Omsk hemorrhagic fever virus, Kyasanur Forest Disease virus, Ebola virus and Marburg virus.

Travel Risks: Varies depending on the causative agent. Risk areas include Africa, Eastern Europe, Central Asia, the Middle East, and South America.

Clinical Description: An acute onset illness with a fever > 104°F or > 40 °C and any of the following: severe headache, muscle pain, erythemous maculopapular rash on the trunk with fine desquamation 3 to 4 days after rash onset, vomiting, diarrhea, pharyngitis (arenavirus only), abdominal pain, bleeding not related to injury, retrosternal chest pain (arenavirus only), proteinuria (arenavirus only), thrombocytopenia

Case Classification

Suspect:
A case that meets the clinical description as described above with any of the following within the 3 weeks before onset of symptoms:
- Contact with blood or other body fluids of a confirmed case or
- Residence in or travel to a VHF endemic area or
- Work in a laboratory that handles VHF specimens or
- Work in a laboratory that handles bats, rodents, or primates from endemic areas or
- Exposure to semen from a confirmed case of VHF within the 10 weeks of that person’s onset of symptoms

Confirmed:
A case that meets the clinical description as described above with any of the following:
- VHF positive antigen by ELISA from blood or
- VHF identified by culture from blood or tissues or
- VHF nucleic acid (RNA) detected (example: PCR, sequencing, NAAT) from blood or tissue or
- Histopathologic identification of VHF viral antigens from tissues

Critical Reporting Elements
Specify the etiologic/causative agent.
Document relevant travel and deployment history occurring within the incubation period.

Comments
None.

Last update: July 2017
**Hepatitis A (hepatitis A virus)**

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>hepatitis A virus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Present worldwide</td>
</tr>
</tbody>
</table>
| Clinical Description  | An acute illness with a discrete onset of any of the following: fever, headache, malaise, anorexia, nausea, vomiting, diarrhea, or abdominal pain, and either of the following:  
  • Jaundice or elevated total bilirubin levels ≥ 3.0 mg/dl or  
  • Elevated serum alanine aminotransferase (ALT) liver test levels > 200 IU/L |

**Case Classification**

*Confirmed:*
In the absence of a more likely diagnosis, a case that meets the clinical description as described above with any of the following:
  • Epidemiologically linked to a laboratory-confirmed case 15 to 50 days before the onset of symptoms or  
  • Hepatitis A positive IgM antibody from serum* or  
  • Hepatitis A virus nucleic acid (RNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen

**Critical Reporting Elements**

Document relevant travel and deployment history occurring within the incubation period.
Document if the case patient works in, lives in, or attends a high transmission setting such as food handling, day care, school, group living, healthcare, training center, or ship.
Note the patient’s hepatitis A immunization history.

**Comments**

*Not otherwise ruled out by PCR/NAAT testing*
Positive hepatitis A IgM results without symptoms DO NOT meet this case definition and, therefore, ARE NOT reportable.
Positive hepatitis A total antibody tests are commonly found in CHCS and DO NOT meet this case definition and, therefore, ARE NOT reportable.
Hepatitis B, Acute & Chronic (hepatitis B virus)

Background

Causative Agent: hepatitis B virus
Travel Risks: N/A
Clinical Description: Acute hepatitis B: An acute illness with a discrete onset of any of the following: fever, headache, malaise, anorexia, nausea, vomiting, diarrhea, or abdominal pain, and either of the following:
- Jaundice
- Elevated serum alanine aminotransferase (ALT) levels > 100 IU/L

Chronic hepatitis B: Ranges from asymptomatic to evidence of liver disease such as cirrhosis or liver cancer.

Case Classification

Acute:
Confirmed:
A case that meets the clinical description of acute hepatitis B as described above with ALL of the following:
- Is not known to have chronic hepatitis B and
- Hepatitis B surface antigen (HBsAg) positive from serum and
- Positive IgM antibody to hepatitis B core antigen (HBc-IgM)

Chronic*:
Confirmed:
A case with ALL of the following:
- Negative IgM antibody to hepatitis B core antigen (HBc-IgM) and
- Hepatitis B positive result in any of the following tests:
  - Hepatitis B surface antigen (HBsAg) from serum or
  - Hepatitis B e antigen (HBeAg) from serum or
  - Hepatitis B nucleic acid (DNA) detected (example: PCR, sequencing, NAAT)

OR

A case with any of the following combinations of tests performed twice separated by at least 6 months*:
- Hepatitis B surface antigen (HBsAg) positive or
- Hepatitis B e antigen (HBeAg) positive or
- Hepatitis B nucleic acid (DNA) detected (example: PCR, sequencing, NAAT)

Critical Reporting Elements
Specify the clinical form of the disease.
Note the patient’s hepatitis B immunization history.

Comments
*For the purposes of this case definition, any positive result among the three laboratory tests mentioned above is acceptable, regardless of other conflicting testing results.
A hepatitis B core antibody test is a total antibody test that includes IgM and IgG unless otherwise specified. Anti-HBc-total DOES NOT meet this case definition and, therefore, IS NOT reportable.

Last update: July 2017
Hepatitis C, Acute & Chronic (hepatitis C virus)

Background

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>hepatitis C virus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>N/A</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>The absence of a more likely diagnosis (which may include evidence of acute liver disease due to other causes or advanced liver disease due to pre-existing chronic hepatitis C virus infection or other causes, such as alcohol exposure, other viral hepatitis, hemochromatosis, etc.) AND one or more of the following:</td>
</tr>
<tr>
<td></td>
<td>• Jaundice or</td>
</tr>
<tr>
<td></td>
<td>• Elevated serum alanine aminotransferase (ALT) levels &gt; 200 IU/L or</td>
</tr>
<tr>
<td></td>
<td>• Peak elevated total bilirubin levels ≥ 3.0 mg/dL</td>
</tr>
</tbody>
</table>

NOTE: All hepatitis C virus cases in each classification category should be >36 months of age, unless known to have been exposed non-perinatally.

Case Classification

Acute:

Probable:
A case that meets the clinical description as described above with ALL of the following:
- No hepatitis C virus detection test reported and
- Hepatitis C virus positive antibody (anti-hepatitis C virus) and
- No record of a test conversion* within the past 12 months

Confirmed:
A case that meets the clinical description as described above with any of the following:
- Hepatitis C virus nucleic acid (RNA) detected (example: PCR, sequencing, NAAT) for hepatitis C virus RNA positive (including qualitative, quantitative, or genotype testing) or
- Hepatitis C virus positive antigen from any clinical specimen

OR

In the absence of a more likely diagnosis, a case with documented test conversion* within 12 months among any of the following tests:
- Hepatitis C virus antibody or
- Hepatitis C virus antigen or
- Hepatitis C virus nucleic acid (RNA) test (example: PCR, sequencing, NAAT) (in a patient without a prior diagnosis of hepatitis C virus infection)

Chronic:

Probable:
A case with ALL of the following:
- Does not meet the clinical description or has no report of clinical criteria and
- No hepatitis C virus RNA detection test reported and
- Hepatitis C virus positive antibody (anti-hepatitis C virus) and
- No record of a test conversion* within the past 12 months
**Confirmed:**
A case with **ALL** of the following:
- Does not meet the clinical description or has no report of clinical criteria and
- No record of a test conversion* within the past 12 months and
- Hepatitis C virus positive result in any of the following tests:
  - Hepatitis C virus nucleic acid (RNA) detected (example: PCR, sequencing, NAAT) or
  - Hepatitis C virus positive antigen

**Critical Reporting Elements**
Specify the clinical form of the disease if known.

**Comments**
*Test conversion refers to a documented lab result of 1) hepatitis C negative antibody, 2) hepatitis C negative antigen, or 3) hepatitis C nucleic acid not detected, followed within 12 months by a positive result of any of these tests.

An acute case of hepatitis C should be reported as a chronic case of hepatitis C if a positive NAT for hepatitis C virus RNA or a positive hepatitis C virus antigen is reported one year or longer after acute case onset.

A confirmed acute case may not be reported as a probable chronic case (i.e., hepatitis C virus antibody positive, but with an unknown hepatitis C virus RNA NAT or antigen status).

A chronic hepatitis C case that has already been reported in the past should not be reported again.
Influenza-Associated Hospitalization (Influenza virus)

COMMON NAME: Seasonal flu

INCLUDES: People younger than 65 years of age who are admitted to the hospital because of influenza

EXCLUDES: Non-hospitalized influenza cases and *Haemophilus influenza*. See *Haemophilus influenza* case definition.

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>Influenza virus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Present worldwide</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>An acute viral disease of the respiratory tract characterized by fever, chills, cough, sore throat, runny or stuffy nose, muscle or body aches, headache, and fatigue.</td>
</tr>
</tbody>
</table>

**Case Classification**

**Confirmed:**

A case that meets the clinical description as described above with **ALL** of the following:

- Younger than 65 years of age and
- Any positive influenza laboratory test (example: culture, DFA, IFA, rapid, PCR)

AND

- Hospital admission date was ≤ 14 days after a positive influenza test or
- Hospital admission date was ≤ 3 days before a positive influenza test

**Critical Reporting Elements**

Specify the virus type (A or B) and subtype (example: H3N2, H1N1) if available.

Note the patient’s influenza immunization history.

**Comments**

Hospitalization is defined as an admission to an inpatient ward of a hospital, or a medical transfer or evacuation to a facility with a higher level of care. Patients admitted for observation and discharged the same day are considered hospitalized for this case definition. An overnight stay is not required. Emergency room or outpatient clinic visits that do not result in hospital admission are not considered hospitalizations.

Report co-infections with other organisms, like SARS CoV-2, separately as individual RMEs.

---

Last update: July 2017
Legionellosis (*Legionella* species)

**COMMON NAME:** Legionnaire’s disease, Pontiac fever

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th><em>Legionella</em> species</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>N/A</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>Legionellosis is associated with three clinically and epidemiologically distinct illnesses:</td>
</tr>
</tbody>
</table>

**Legionnaires’ disease (LD):**
An illness that presents as pneumonia with clinically compatible evidence defined as ONE of the following:
- A clinical or radiographic diagnosis of pneumonia in the medical record OR
- Clinical symptoms consistent with a diagnosis of pneumonia that must include acute onset of lower respiratory illness with fever and/or cough and may include myalgia, shortness of breath, malaise, chest discomfort, confusion, nausea, diarrhea, or abdominal pain

**Pontiac fever (PF):** A milder illness without pneumonia. Symptoms may vary but must include acute symptom onset of one or more of the following: fever, chills, myalgia, malaise, fatigue, headaches, nausea and/or vomiting.

**Extrapulmonary Legionellosis (XPL):** *Legionella* can cause disease at sites outside the lungs (e.g., associated with endocarditis, wound infection, joint infection, graft infection).

**Case Classification**

**Legionnaires’ disease (LD) or Pontiac fever (PF):**

**Suspect:**
A case that meets the LD or PF clinical description as described above with any of the following:
- At least a four-fold increase of antibody titer against specific species or serogroups of *Legionella* other than *L. pneumophila* serogroup 1 (example: *L. micdadei*, *L. pneumophila* serogroup 6) between paired acute and convalescent sera or
- At least four-fold increase of antibody titer against multiple species of pooled *Legionella* antigens between paired acute and convalescent sera or
- *Legionella* specific positive antigen by DFA or other similar method from lower respiratory secretions, lung tissue, pleural fluid, or extrapulmonary sites or
- Histopathologic identification of *Legionella* antigen by IHC from lower respiratory secretions, lung tissue, pleural fluid, or extrapulmonary sites

**Probable:**
A case that meets either of the following:
- The LD clinical description as described above and is epidemiologically linked in the 14 days prior to symptom onset or
• The PF clinical description as described above and is epidemiologically linked† in the 3 days prior to symptom onset

Confirmed:
A case that meets the LD or PF clinical description as described above with any of the following:
• Any *Legionella* species identified by culture from lower respiratory secretions, lung tissue, pleural fluid, or extrapulmonary sites or
• Any *Legionella* species’ nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from lower respiratory secretions, lung tissue, pleural fluid, or extrapulmonary sites or
• *L. pneumophila* serogroup 1 positive antigen from urine or
• At least a four-fold increase of antibody titer against *L. pneumophila* serogroup 1

Extrapulmonary Legionnaires’ disease (XPL):

Suspect:
A case that meets the XPL clinical description as described above with one of the following:
• At least a four-fold increase of antibody titer against specific species or serogroups of *Legionella* other than *L. pneumophila* serogroup 1 (example: *L. micdadei*, *L. pneumophila* serogroup 6) between paired acute and convalescent sera or
• At least a four-fold increase of antibody titer against multiple species of pooled *Legionella* antigens between paired acute and convalescent sera or
• *Legionella* specific positive antigen by DFA or other similar method from lower respiratory secretions, lung tissue, pleural fluid, or extrapulmonary sites or
• Histopathologic identification of *Legionella* antigen by IHC from lower respiratory secretions, lung tissue, pleural fluid, or extrapulmonary sites

Confirmed:
A case that meets the XPL clinical description as described above with any of the following laboratory evidence at an extrapulmonary site:
• *Legionella* identified by culture from the extrapulmonary site or
• *Legionella* species nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from the extrapulmonary site or
• *L. pneumophila* serogroup 1 positive antigen from urine or
• At least a four-fold increase of antibody titer against *L. pneumophila* serogroup 1 between acute and convalescent sera

Critical Reporting Elements
Specify the clinical form of the disease.
Document relevant travel and deployment history occurring within the incubation period.

Comments
†Epidemiologically linked includes the following prior to symptom onset:
• Exposure to a setting with a confirmed source of *Legionella* (e.g., positive environmental sampling result associated with a cruise ship, public accommodation, cooling tower, etc.), or
• Exposure to a setting with a suspected source of *Legionella* that is associated with at least one confirmed case

Last update: January 2022
Leishmaniasis (Leishmania species)

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>Leishmania species</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Most common in areas from Northern Argentina to Southern Texas, Southern Europe, Asia, the Middle East, and Africa</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>Organisms of the genus Leishmania cause two major forms of disease:</td>
</tr>
</tbody>
</table>

- **Cutaneous, Mucosal, and Mucocutaneous:** An illness characterized by one or more lesions on uncovered parts of the body. The face, neck, arms, and legs are most common. A nodule appears at site of inoculation, becomes an indolent ulcer, and eventually heals leaving a depressed scar. Certain strains can disseminate and cause disfiguring mucosal lesions (mucosal/mucocutaneous leishmaniasis).

- **Visceral:** A chronic systemic illness with persistent irregular fever, hepatosplenomegaly, lymphadenopathy, pancytopenia, and weight loss.

**Case Classification**

**Cutaneous, Mucosal, and Mucocutaneous:**

**Confirmed:**

A case that meets any of the clinical descriptions as described above with any of the following:

- Microscopic identification of Leishmania from a lesion or
- Leishmania identified by culture from a lesion or
- Leishmania nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from a lesion biopsy specimen or lesion aspirate

**Visceral:**

**Confirmed:**

A case that meets any of the clinical descriptions as described above with any of the following:

- Microscopic identification of Leishmania from bone marrow, spleen, liver, lymph node, or blood or
- Leishmania identified by culture from bone marrow, spleen, liver, lymph node, or blood, or
- Leishmania nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from bone marrow, spleen, liver, lymph node, or blood or
- Leishmania positive antibody (example: direct agglutination, rK39 assay) from serum

**Critical Reporting Elements**

Specify the clinical form of the disease.
Document relevant travel and deployment history occurring within the incubation period.

**Comments**

None.

Last update: July 2017
**Leprosy (Mycobacterium leprae)**

**COMMON NAME:** Hansen’s disease

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th><em>Mycobacterium leprae</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>N/A</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>A chronic bacterial disease characterized by the involvement primarily of skin as well as peripheral nerves and the mucosa of the upper airway. The following characteristics are typical of the major forms of the disease, though these classifications are assigned after a case has been laboratory confirmed.</td>
</tr>
</tbody>
</table>

**Tuberculoid:** An illness characterized by one or few well-demaracated, hypopigmented, and hypoesthetic or anesthetic skin lesions, frequently with active, spreading edges and a clearing center; peripheral nerve swelling or thickening also may occur.

**Lepromatous:** An illness characterized by a number of erythematous papules and nodules or an infiltration of the face, hands, and feet with lesions in a bilateral and symmetrical distribution that progress to thickening of the skin, possibly with reduced sensation.

**Borderline (dimorphous):** An illness characterized by skin lesions characteristic of both the tuberculoid and lepromatous forms.

**Indeterminate:** An illness characterized by early lesions, usually hypopigmented macules, without developed tuberculoid or lepromatous features but with definite identification of acid-fast bacilli in Fite stained sections.

**Case Classification**

**Confirmed:**

A case that meets the clinical description as described above with any of the following:

- Microscopic identification of acid fast bacilli in skin or dermal nerve from a biopsy of a skin lesion using Fite stain, without growth of mycobacteria on conventional media (if performed) or
- Microscopic identification of noncaseating granulomas with peripheral nerve involvement, without growth of mycobacteria on conventional media (if performed)

**Critical Reporting Elements**

Document clinical form of the disease.

Document the source of infection if known.

**Comments**

None.

Last update: July 2017
# Leptospirosis (*Leptospira interrogans*)

**COMMON NAME:** Weil disease

## Background

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th><em>Leptospira interrogans</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Present worldwide; particularly tropical areas</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>An illness characterized by history of fever within the past two weeks and:</td>
</tr>
<tr>
<td></td>
<td>• At least two of the following: Myalgia, headache, jaundice, conjunctival suffusion without purulent discharge, or rash or</td>
</tr>
<tr>
<td></td>
<td>• At least one of the following: aseptic meningitis, GI symptoms, pulmonary complications, cardiac arrhythmias, ECG abnormalities, renal insufficiency, hemorrhage, or jaundice with acute renal failure</td>
</tr>
</tbody>
</table>

## Case Classification

### Probable:
A case that meets the clinical description as described above with any of the following:

- Epidemiologically linked to an exposure event (example: adventure race, triathlon, flooding) with associated confirmed cases or
- *Leptospira* agglutination titer of $\geq 200$ but $< 800$ by MAT in one or more serum specimens or
- *Leptospira* positive antibody by IFA from any clinical specimen or
- Darkfield microscopic identification of *Leptospira* from any clinical specimen or
- *Leptospira* positive IgM antibody from an acute phase serum specimen

### Confirmed:
A case with any of the following:

- *Leptospira* identified by culture from any clinical specimen or
- At least a four-fold increase in *Leptospira* antibody titer between acute and convalescent serum or
- *Leptospira* positive antigen by DFA from tissue or
- *Leptospira* agglutination titer of $\geq 800$ by MAT from serum or
- *Leptospira* nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen

## Critical Reporting Elements

Document relevant travel and deployment history occurring within the incubation period. Document the circumstances under which the case patient was exposed including duty exposure, occupational activities, environmental exposures, or other high risk activities.

## Comments

None.

Last update: July 2017
Listeriosis (Listeria monocytogenes)

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>Listeria monocytogenes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>N/A</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>Invasive listeriosis:</td>
</tr>
</tbody>
</table>

- **Systemic illness**: Manifests most commonly as bacteremia or central nervous system infection. Other manifestations can include pneumonia, peritonitis, endocarditis, and focal infections of joints and bones.
- **Maternal listeriosis**: Generally classified as illness occurring in a pregnant woman or in an infant age ≤28 days. Listeriosis may result in miscarriage/pregnancy loss, pre-term labor, or neonatal infection, while causing minimal or no systemic symptoms in the mother.
- **Neonatal listeriosis**: Commonly manifests as bacteremia, central nervous system infection, and pneumonia, and is associated with high fatality rates. Transmission of Listeria from mother to baby transplacentally or during delivery is almost always the source of early-onset neonatal infections (diagnosed between birth and 6 days), and the most likely source of late-onset neonatal listeriosis (diagnosed between 7–28 days).

Non-invasive Listeria infections:
- Infection manifesting commonly as gastroenteritis with fever, urinary tract infection, or wound infection

**Case Classification**

**Non-maternal and non-neonatal Listeriosis**

**Suspect**: 
*L. monocytogenes* identified by culture from a non-sterile clinical specimen (e.g., stool, urine, wound)

**Probable**: 
*L. monocytogenes* positive laboratory test by a method other than culture (example: EIA, PCR) obtained from a normally sterile site (example: CSF, blood, joint fluid, pleural fluid, pericardial fluid, etc.)

**Confirmed**: 
*L. monocytogenes* identified by culture from specimens obtained from a normally sterile site (example: CSF, blood, joint fluid, pleural fluid, pericardial fluid, etc.)

**Maternal and Neonatal Listeriosis**

**Probable**: 
A maternal or neonatal case with any of the following:
- A mother or neonate who are epidemiologically linked’ to each other and does not meet the confirmatory case classification or
- *Maternal Listeriosis: L. monocytogenes* positive laboratory test by a method other than culture (example: EIA, PCR) collected from products of conception (e.g., chorionic villi, placenta, fetal tissue, umbilical cord blood, amniotic fluid) collected at the time of delivery or
• **Neonatal Listeriosis**: *L. monocytogenes* positive laboratory test by a method other than culture (example: EIA, PCR) collected from a non-sterile neonatal specimen (e.g., meconium, tracheal aspirate, but not products of conception) collected within 48 hours of delivery

**Confirmed:**
A maternal or neonatal case with any of the following:

• **Maternal Listeriosis**: *L. monocytogenes* identified by culture from specimens obtained from products of conception (e.g., chorionic villi, placenta, fetal tissue, umbilical cord blood, amniotic fluid) collected at the time of delivery or

• **Neonatal Listeriosis**: *L. monocytogenes* identified by culture from a non-sterile neonatal specimen (e.g., meconium, tracheal aspirate, but not products of conception) collected within 48 hours of delivery

**Critical Reporting Elements**
Document source of infection if known.

**Comments**

†Epidemiologic linkage for probable maternal/neonatal cases:

• Maternal epi-link:
  o A mother who does not meet the confirmed case classification BUT
    ▪ Gave birth to a neonate who meets the confirmed or probable case classification AND
    ▪ Neonatal specimen was collected up to 28 days of birth

• Neonatal epi-link:
  o Neonate(s) who do not meet the confirmed case classification AND
    ▪ Whose mother meets the confirmed or probable case classification or
    ▪ A neonate who meets the clinical description as described above whose mother has a positive culture or positive test than culture (example: EIA, PCR) from a normally sterile site (e.g., blood or cerebrospinal fluid or, less commonly: pleural, peritoneal, pericardial, hepatobiliary, or vitreous fluid; orthopedic site such as bone, bone marrow, or joint; or other sterile sites including organs such as spleen, liver, and heart, etc.)

Miscarriage/pregnancy loss is considered a maternal outcome and should be reported as a single case in the mother. Cases in neonates and mothers should be reported separately when each meets the case definition. A case in a neonate should be reported if live-born.

Last update: January 2022
**Lyme Disease** (*Borrelia burgdorferi*)

**Background**

**Causative Agent**  *Borrelia burgdorferi sensu lato*

**Travel Risks**  Most common in North America, Europe, and Northern Asia

**Clinical Description**  A systemic, tick-borne disease with protean manifestations, including dermatologic, rheumatologic, neurologic, and cardiac abnormalities. The most common clinical marker for the disease is *erythema migrans* (EM) or “bulls-eye rash”, the initial skin lesion that occurs in 60%-80% of patients. EM typically begins as a red macule or papule and expands over a period of days to weeks to form a large round lesion, often with partial central clearing. A single primary lesion must reach greater than or equal to 5 cm in size across its largest diameter. Secondary lesions also may occur. Annular erythematous lesions occurring within several hours of a tick bite represent hypersensitivity reactions and do not qualify as EM. For most patients, the expanding EM lesion is accompanied by other acute symptoms, particularly fatigue, fever, headache, mildly stiff neck, arthralgia, or myalgia. These symptoms are typically intermittent.

Late clinical manifestations of the disease include: severe headaches and neck stiffness, additional EM Rashes to the body, arthritis with severe joint pain and swelling (particularly to the knees and other large joints), facial palsy (loss of muscle tone or droop on one or both sides of the face), intermittent pain in tendons, muscles, joints, and bones, heart palpitations or an irregular heartbeat, episodes of dizziness or short breath, inflammation of the brain and spinal cord, nerve pain, shooting pains, numbness, or tingling in the hands or feet, and problems with short term memory.

**Case Classification**

**Suspect:**

A case with any of the following:

- EM without a known exposure* and no laboratory information available or
- A case with no clinical information available and any of the following:
  - *B. burgdorferi* identified by culture from any clinical specimen or
  - *B. burgdorferi* positive IgM/IgG antibody by EIA or IFA followed by *B. burgdorferi* positive IgM Western Blot\(^\text{\textsuperscript{\textcircled{Q}}}\) only when ≤ 30 days of symptom onset or
  - *B. burgdorferi* positive IgM/IgG antibody by EIA or IFA followed by *B. burgdorferi* positive IgG Western Blot\(^\text{\textsuperscript{\textcircled{\Omega}}}\) at any point during illness or
  - *B. burgdorferi* positive IgG antibody by Western Blot\(^\text{\textsuperscript{\textcircled{\Omega}}}\)

**Probable:**

A case of provider-diagnosed Lyme disease and any of the following:

- *B. burgdorferi* identified by culture from any clinical specimen or
- *B. burgdorferi* positive IgM/IgG antibody by EIA or IFA followed by *B. burgdorferi* positive IgM Western Blot\(^\text{\textsuperscript{\textcircled{Q}}}\) only when ≤ 30 days of symptom onset or
- *B. burgdorferi* positive IgM/IgG antibody by EIA or IFA followed by *B. burgdorferi* positive IgG Western Blot\(^\text{\textsuperscript{\textcircled{\Omega}}}\) at any point during illness or
- *B. burgdorferi* positive IgG antibody by Western Blot\(^\text{\textsuperscript{\textcircled{\Omega}}}\)
Confirmed:
A case with any of the following:

- EM with a known exposure* in a high endemic area or
- EM with a known exposure* in a non-endemic area and any of the following:
  - *B. burgdorferi* identified by culture from any clinical specimen or
  - *B. burgdorferi* positive IgM/IgG antibody by EIA or IFA followed by *B. burgdorferi*
    positive IgM Western BlotΩ only when ≤ 30 days of symptom onset or
  - *B. burgdorferi* positive IgM/IgG antibody by EIA or IFA followed by *B. burgdorferi*
    positive IgG Western Blot¥ at any point during illness or
  - *B. burgdorferi* positive IgG antibody by Western Blot¥

OR

- A case with at least one late manifestation (as described above) and any of the following:
  - *B. burgdorferi* identified by culture from any clinical specimen or
  - *B. burgdorferi* positive IgM/IgG antibody by EIA or IFA followed by *B. burgdorferi*
    positive IgM Western BlotΩ only when ≤ 30 days of symptom onset or
  - *B. burgdorferi* positive IgM/IgG antibody by EIA or IFA followed by *B. burgdorferi*
    positive IgG Western Blot¥ at any point during illness or
  - *B. burgdorferi* positive IgG antibody by Western Blot¥

Critical Reporting Elements
Document the circumstances under which the case patient was exposed including duty exposure, occupational activities, environmental exposures, or other high risk activities.

Comments
*Exposure is defined as having been (less than or equal to 30 days before onset of EM) in wooded, brushy, or grassy areas (i.e., potential tick habitats) in a county in which Lyme disease is endemic. A history of tick bite is not required.

Ω An IgM immunoblot is considered positive if two of the following three bands are present: 24 kDa (OspC), 39 kDa (BmpA), and 41 kDa (Fla).

¥ An IgG immunoblot is considered positive if five of the following ten bands are present: 18 kDa, 21 kDa (OspC), 28 kDa, 30 kDa, 39 kDa (BmpA), 41 kDa (Fla), 45 kDa, 58 kDa (not GroEL), 66 kDa, and 93 kDa.

Depending upon the assay, OspC could be indicated by a band of 21, 22, 23, 24 or 25 kDa.

Endemicity is defined as a county in which at least two confirmed cases have been acquired or in which established populations of a known tick vector are infected with *B. burgdorferi*.
Malaria (*Plasmodium* species)

**Background**

**Causative Agent** *Plasmodium* species

**Travel Risks** Most common in tropical and subtropical areas of South America, Africa, and Southeastern Asia.

**Clinical Description** Malaria is characterized most often by fever, chills, sweats, headaches, muscle pains, nausea, vomiting and fatigue. Persons with severe malaria may experience confusion, coma, neurologic focal signs, severe anemia, and respiratory difficulties.

**Case Classification**

**Suspect:**
Plasmodium positive antigen by rapid diagnostic test (RDT)

**Confirmed:**
A case with any of the following:
- Microscopic identification of the specific *Plasmodium* species from blood or
- Microscopic identification of *Plasmodium* from blood, but not able to determine the specific species of malaria or
- *Plasmodium* nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from blood

**Critical Reporting Elements**

Specify the species if known.
Document relevant travel and deployment history occurring within the incubation period.
Document chemoprophylaxis regimen.

**Comments**

Report dual infections of different *Plasmodium* species separately.

Last update: July 2017
Measles (measles virus)

COMMON NAME: Rubeola

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>measles virus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Present worldwide</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>An acute illness characterized by <strong>ALL</strong> of the following:</td>
</tr>
<tr>
<td></td>
<td>• Generalized, maculopapular rash lasting ≥ 3 days and</td>
</tr>
<tr>
<td></td>
<td>• Temperature ≥ 101°F or 38.3°C and</td>
</tr>
<tr>
<td></td>
<td>• Cough or coryza (inflammation of nasal mucous membranes) or conjunctivitis (inflammation of the eye)</td>
</tr>
</tbody>
</table>

**Case Classification**

**Probable:**
In the absence of a more likely diagnosis, a case that meets the clinical description as described above where lab results are not available and there is no epidemiologic link to a laboratory-confirmed case

**Confirmed:**
Any acute febrile rash illness with any of the following:
- Measles virus identified by culture* from any clinical specimen or
- Measles virus nucleic acid* (RNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen or
- Seroconversion from a negative measles IgG followed by a positive measles IgG in a convalescent sera or
- Significant rise of measles IgG titer between 2 serum samples* or
- Measles positive IgM antibody*† from serum or
- Epidemiologically linked to a laboratory-confirmed case

**Critical Reporting Elements**
Document relevant travel and deployment history occurring within the incubation period.
Note the patient’s measles immunization history.

**Comments**
*Not explained by MMR vaccination during the previous 6-45 days.
†Not otherwise ruled out by other confirmatory testing or more specific measles testing in a public health laboratory.

Last update: July 2017
Meningococcal Disease (Neisseria meningitidis)

EXCLUDES: Viral/aseptic meningitis

Background

Causative Agent: Neisseria meningitidis
Travel Risks: Present worldwide
Clinical Description: Meningococcal disease typically presents in one of two forms: meningitis or septicemia. However, other manifestations might be observed. Meningococcal disease manifests most commonly as meningitis and/or meningococcemia that may progress rapidly to purpura fulminans (a hemorrhagic condition and clotting disorder which manifests as blood spots, bruising and discoloration of the skin), shock, and death.

Case Classification

Suspect:
A case with any of the following:
- Clinical purpura fulminans in the absence of a positive blood culture or
- Microscopic identification of gram-negative diplococci from a normally sterile body site (example: blood or CSF or, less commonly, joint, pleural, or pericardial fluid)

Probable:
A case with the following:
- Histopathologic identification of N. meningitidis antigen by IHC from formalin-fixed tissue or
- N. meningitidis positive antigen by latex agglutination from CSF

Confirmed:
A case with any of the following:
- N. meningitidis nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from a specimen obtained from a normally sterile body site (example: blood or CSF or, less commonly, joint, pleural, or pericardial fluid) or
- N. meningitidis identified by culture from a normally sterile body site (example: blood, CSF, or less commonly, synovial, pleural, or pericardial fluid) or from purpuric lesions

Critical Reporting Elements
Specify the serogroup (A, B, C, Y, Z, W135) if known.
Note the patient’s meningococcal immunization history.
Specify the clinical form of the disease.

Comments
None.

Last update: July 2017
## Mumps (mumps virus)

### Background

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>mumps virus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Present worldwide</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>Acute swelling of the parotid or other salivary gland(s) lasting at least 2 days. It can present as orchitis, oophoritis, aseptic meningitis, encephalitis (rarely), mastitis, pancreatitis (usually mild), hearing loss, and in rare instances can lead to permanent nerve deafness.</td>
</tr>
</tbody>
</table>

### Case Classification

**Suspect:**
A case with any of the following:
- In the absence of a more likely diagnosis, a case that meets the clinical description as described above or
- Any positive mumps laboratory result without clinical symptoms

**Probable:**
In the absence of a more likely diagnosis, a case that meets the clinical description as described above with any of the following:
- Mumps positive IgM antibody from serum or
- Epidemiologically linked to a probable or confirmed case or
- Epidemiologically linked to a group/community defined by public health during an outbreak of mumps

**Confirmed:**
A case the meets the clinical description as described above with any of the following:
- Mumps nucleic acid (RNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen or
- Mumps identified by culture from any clinical specimen

### Critical Reporting Elements

Document relevant travel and deployment history occurring within the incubation period.
Note the patient’s mumps immunization history.

### Comments

None.

Last update: July 2017
## Norovirus Infection (Norwalk virus)

<table>
<thead>
<tr>
<th><strong>Background</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Causative Agent</strong></td>
<td><em>Norwalk virus</em></td>
</tr>
<tr>
<td><strong>Travel Risks</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Clinical Description</strong></td>
<td>An acute, highly contagious viral gastroenteritis characterized by vomiting, watery non-bloody diarrhea with abdominal cramps, and nausea. Vomiting is the most commonly reported symptom and occurs in more than 50% of cases. Low-grade fever also occasionally occurs. Symptoms usually last 24 to 60 hours.</td>
</tr>
</tbody>
</table>

### Case Classification

**Probable:**

A case that meets the clinical description described above and that is epidemiologically linked to a confirmed case

**Confirmed:**

A case with any of the following:

- Norovirus nucleic acid (RNA) detected (example: PCR, sequencing, NAAT) from stool or vomitus or
- Microscopic identification of norovirus (by electron microscopy) from stool or vomitus

### Critical Reporting Elements

Document the source of infection if known.

Document if the case patient works in, lives in, or attends a high transmission setting such as food handling, day care, school, group living, healthcare, training center, or ship.

### Comments

None.
Novel and Variant Influenza (Influenza A virus)

INCLUDES: Hospitalized and non-hospitalized cases.

EXCLUDES: Seasonal influenza or influenza caused by current circulating influenza H1 and H3 viruses. Note that influenza A (H1N1) pdm09 is no longer reportable as novel influenza.

Background

Causative Agent: Novel and variant subtypes of influenza A virus
Travel Risks: Most common among poultry in Bangladesh, China, Egypt, India, Indonesia, and Vietnam
Clinical Description: An acute respiratory illness with fever often indistinguishable from seasonal influenza.

Case Classification

Probable:
A case that meets the clinical description as described above with no or inconclusive laboratory testing for novel or variant influenza A virus and that meets any of the following:

- Contact with a confirmed case of novel or variant influenza

OR

- Travel to an area with known cases of novel or variant influenza and
- Exposure to animals known to transmit novel or variant influenza (e.g., birds or pigs)

Confirmed:
A case with any of the following:

- Novel or variant influenza A virus identified by culture or
- Novel or variant influenza A virus nucleic acid (RNA) detected (example: PCR, sequencing, NAAT) or
- Novel or variant influenza A virus identified by another testing method as determined by DoD

Critical Reporting Elements

Document relevant travel and deployment history occurring within the incubation period.
Document the circumstances under which the case patient was exposed including duty exposure, occupational activities, environmental exposures, or other high risk activities.
Document if the case patient works in, lives in, or attends a high transmission setting such as food handling, day care, school, group living, healthcare, training center, or ship.

Comments
None.

Last update: July 2017
Outbreak or Disease Cluster

Background

- Causative Agent: Various
- Travel Risks: Present worldwide
- Clinical Description: An outbreak is defined as the occurrence of a medical condition that exceeds the baseline or expected rate within a specific place or group of people over a given period of time. Outbreaks can be caused by a variety of etiologic agents, transmitted person-to-person or via a common source, resulting in mild or serious illness. There is not a minimum number of cases that constitutes an outbreak. In some instances a single case can constitute an outbreak depending on the organism (example: smallpox). The rate increase that should trigger reporting will vary according to the circumstances surrounding the event and requires exercise of professional judgment.

Case Classification

While the decision to report an outbreak requires professional judgment, outbreaks should be reported when an increase in illness leads local public health personnel to: (a) identify cases, (b) seek causes, or (c) institute control measures. When in doubt, report, but know that Service public health authorities are most interested in the following:

- Illnesses causing a rapid rise in numbers of affected persons
- Severe illnesses such as hospitalized cases
- Illnesses which appear to be limited to a specific group (demographic, occupational, etc.)
- Illnesses indicative of highly infectious or virulent organisms requiring rapid implementation of control measures
- Illnesses which affect or have the potential to affect mission readiness
- Illnesses leading to control measure recommendations which are invasive, involve mass prophylaxis, or are potentially resource intensive
- Illnesses with the potential to attract media attention or generate public concern
- Illnesses which may prompt an installation commander to exercise public health emergency powers (i.e., illnesses indicative of a public health emergency or act of bioterrorism)
- Vaccine-preventable illnesses occurring in a highly vaccinated population

Critical Reporting Elements

Document location, source of outbreak if known or suspected, case symptoms and likely etiological agent if known, number affected, group affiliation (example: military unit, boy scouts), beginning and end dates, and actions taken to mitigate outbreak.

Comments

Outbreaks are reportable regardless of whether the etiologic agent itself is known or on the reportable disease list. If the etiologic agent is on the reportable disease list, then also report each case individually in addition to reporting the outbreak, unless otherwise directed by your service point of contact (pg 9).

Last update: July 2017
Pertussis (*Bordetella pertussis*)

**COMMON NAME:** Whooping Cough

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th><em>Bordetella pertussis</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Clinical Description**

In the absence of a more likely diagnosis, a cough lasting ≥ 2 weeks with at least one of the following symptoms:

- Paroxysms of coughing (a series of coughs in rapid succession with increasing intensity) or
- Inspiratory “whoop” or
- Post-tussive vomiting or
- Apnea (with or without cyanosis)

**Case Classification**

**Probable:**

A case with any of the following:

- In the absence of a more likely diagnosis, a case that meets the clinical description as described above or
- A cough of any duration that meets the clinical description as described above and is epidemiologically linked to a confirmed case

**Confirmed:**

A case with an acute cough illness of any duration with any of the following:

- *B. pertussis* identified by culture from any clinical specimen or
- *B. pertussis* nucleic acid (DNA) detected (example: PCR, sequencing NAAT)

**Critical Reporting Elements**

Note the patient’s pertussis immunization history.

**Comments**

None.

Last update: January 2022
**Plague (Yersinia pestis)**

**Background**

**Causative Agent**  
*Yersinia pestis*

**Travel Risks**  
Most common in rural areas of Central and Southern Africa, Central Asia and the Indian subcontinent, the Northeastern South America, and parts of the Southwestern United States

**Clinical Description**  
An illness characterized by fever as reported by the patient or healthcare provider with or without one or more of the following specific clinical manifestations:

- **Bubonic**: Regional lymphadenitis (bubo) in the area of the infected flea bite. Most often (> 90%) inguinal; alternatively cervical or axillary.

- **Septicemic**: Without an evident bubo. May be a complication of any of the other forms of plague, or may be the presenting syndrome.

- **Pneumonia**: Pneumonic plague, resulting from hematogenous spread in bubonic or septicemic cases (secondary pneumonic plague) or inhalation of infectious droplets (primary pneumonic plague).

- **Pharyngeal**: Pharyngitis and cervical lymphadenitis resulting from exposure to larger infectious droplets or ingestion of infected tissues.

**Case Classification**

**Suspect:**
A case with any of the following:

- Meets the clinical description as described above, has no laboratory testing, and is epidemiologically linked*

- No clinical information is available and meets any of the following:
  - *Y. pestis* positive antibody against fraction 1 (F1) antigen from serum in a patient with no history of plague vaccination or
  - *Y. pestis* positive antigens, including F1 antigen by DFA from any clinical specimen or
  - Histopathologic identification of *Y. pestis* positive antigen, including F1 antigen, by IHC from any clinical specimen or
  - *Y. pestis* nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen or
  - At least a four-fold change (increase or decrease) of antibody titer against F1 antigen between paired acute and convalescent sera or
  - *Y. pestis* identified by culture from any clinical specimen that is validated by a secondary assay (e.g., bacteriophage lysis assay, DFA)

**Probable:**
In the absence of a more likely diagnosis, a case that meets the clinical description as described above without epidemiologic linkage* with any of the following:

- *Y. pestis* positive antibody against F1 antigen from serum in a patient with no history of plague vaccination or

- *Y. pestis* positive antigens, including F1 antigen by DFA from any clinical specimen or
• Histopathologic identification of *Y. pestis* positive antigen, including F1 antigen, by IHC from any clinical specimen or
• *Y. pestis* nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen

**Confirmed:**
A case that meets the clinical description as described above with any of the following:
• *Y. pestis* identified by culture from any clinical specimen that is validated by a secondary assay (e.g., bacteriophage lysis assay, direct fluorescent antibody assay) or
• At least a four-fold change (increase or decrease) of antibody titer against F1 antigen between paired acute and convalescent sera

OR

A case that meets the clinical description as described above, is epidemiologically linked*, and has any of the following:
• *Y. pestis* positive antibody against F1 antigen from serum in a patient with no history of plague vaccination or
• *Y. pestis* positive antigens, including F1 antigen by DFA from any clinical specimen or
• Histopathologic identification of *Y. pestis* positive antigen, including F1 antigen, by IHC from any clinical specimen
• *Y. pestis* nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen

**Critical Reporting Elements**
Document the clinical form of the infection.
Document relevant travel and deployment history occurring within the incubation period.
Document the circumstances under which the case patient was exposed including duty exposure, occupational activities, environmental exposures, or other high risk activities.

**Comments**
*Epidemiologically linked cases include any of the following:
• A person who is epidemiologically linked to a person or animals with laboratory evidence within the prior two weeks of symptom onset date or
• Close contact with a confirmed pneumatic plague case, including but not limited to presence within six feet of a person with active cough due to pneumatic plague or
• A person that lives in, or has traveled within two weeks of illness onset to a geographically-localized area with confirmed plague epizootic activity in fleas or animals as determined by the relevant local authorities

Serial or subsequent plague infections in one individual should only be reported as a new case if there is a new epidemiologically-compatible exposure and new onset of symptoms.

Last update: January 2022
# Poliomyelitis (poliovirus)

## Background

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>poliovirus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Most common in Afghanistan and Pakistan</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>An illness characterized by an acute onset of a flaccid paralysis of one or more limbs with decreased or absent tendon reflexes in the affected limbs, without other apparent cause, and without sensory or cognitive loss.</td>
</tr>
</tbody>
</table>

## Case Classification

<table>
<thead>
<tr>
<th>Paralytic:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Probable:</td>
<td>A case that meets the clinical description as described above</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Confirmed:</th>
<th>A case that meets the clinical description as described above with any of the following:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• A neurologic deficit 60 days after onset of initial symptoms or</td>
<td></td>
</tr>
<tr>
<td>• Death or</td>
<td></td>
</tr>
<tr>
<td>• Unknown follow-up status</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Non-paralytic:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Confirmed:</td>
<td>A case without symptoms of paralytic poliomyelitis with <strong>ALL</strong> of the following</td>
</tr>
<tr>
<td>• Poliovirus identified by culture from any clinical specimen and</td>
<td></td>
</tr>
<tr>
<td>• Confirmatory typing and sequencing by a CDC Poliovirus Laboratory, as needed</td>
<td></td>
</tr>
</tbody>
</table>

## Critical Reporting Elements

Specify the clinical form of the disease.

Document relevant travel and deployment history occurring within the incubation period.

Note the patient’s poliomyelitis immunization history.

## Comments

None.
Post-Exposure Prophylaxis (PEP) against Rabies

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>N/A</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>Rabies is a zoonotic disease caused by RNA viruses in the family Rhabdoviridae, genus Lyssavirus. Rabies virus is present in the saliva and central nervous system (CNS) tissue of rabid mammals. If a person has been exposed (or reasonably presumed to have been exposed) to a rabid (or potentially rabid) animal, then rabies post-exposure prophylaxis (PEP) is warranted for the prevention of human rabies. PEP can be in the form of anti-rabies vaccine, human rabies immunoglobulin (HRIG) or both depending on the circumstances.</td>
</tr>
</tbody>
</table>

**Case Classification**

**Confirmed:**
A case that meets the exposure criteria* as defined below in which rabies PEP is initiated and a full rabies exposure risk assessment is completed

**Critical Reporting Elements**
Specify the implicated animal species if known.
Anatomical site of exposure.
Document the circumstances under which the case patient was potentially exposed including deployment and duty exposure, occupational activities, environmental exposures, or other high risk activities.
Note the patient’s rabies immunization history.
Specify reason(s) for discontinuation if PEP was discontinued.

**Comments**
Report all cases receiving PEP that met the exposure criteria even if PEP is subsequently terminated due to the animal being deemed rabies free.

*Exposure is defined as one or more of the following:
- Any bite, scratch or other situation in which saliva or CNS tissue of a rabid or potentially rabid animal could have entered an open or fresh wound or come in contact with a mucous membrane by entering the eye, mouth or nose or
- Inadvertent contact with a bat’s saliva or CNS tissue or circumstance in which bat exposure cannot be ruled out (ex: finding a bat in a room with an unattended child, a mentally impaired person, or a sleeping person) or
- Recipient of organ donations from suspected or known human cases of rabies

Last update: January 2020
## Q fever (Coxiella burnetii)

### Background

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th><strong>Coxiella burnetii</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Present worldwide; particularly in Africa and the Middle East</td>
</tr>
<tr>
<td>Clinical Description</td>
<td><strong>Acute</strong>: An illness characterized by an acute fever and any of the following: rigors, severe retrobulbar headache, acute hepatitis, pneumonia, or elevated liver enzyme levels.</td>
</tr>
<tr>
<td></td>
<td><strong>Chronic</strong>: An infection that persists for more than 6 months. Newly recognized, culture-negative endocarditis, particularly in a patient with previous valvulopathy or compromised immune system, suspected infection of a vascular aneurysm or vascular prosthesis, or chronic hepatitis, osteomyelitis, osteoarthritis, or pneumonitis in the absence of other known etiology.</td>
</tr>
</tbody>
</table>

### Case Classification

#### Acute:
- **Probable:** A case that meets the clinical description of acute Q fever as described above with any of the following:
  - *C. burnetii* positive IgG titer of $\geq 1:128$ against phase II antigen by IFA
  - *C. burnetii* positive IgM or IgG antibody against phase II antigen by ELISA or latex agglutination

- **Confirmed:** A case that meets any of the following:
  - Epidemiologically linked to a confirmed case or
  - A case that meets the clinical description of acute Q fever as described above with any of the following:
    - At least a four-fold change (increase or decrease) of IgG antibody titer against phase II antigen by IFA between paired acute and convalescent sera separated by 3-6 weeks or
    - *C. burnetii* nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen or
    - Histopathologic identification of *C. burnetii* antigen by IHC from any clinical specimen or
    - *C. burnetii* identified by culture from any clinical specimen

#### Chronic:
- **Probable:** A case that meets the clinical description of chronic Q fever as described above with *C. burnetii* positive IgG titer of $\geq 1:128$ but $< 1:800$ to phase I antigen by IFA

- **Confirmed:** A case that meets the clinical description of chronic Q fever as described above with any of the following:
  - *C. burnetii* positive IgG titer of $\geq 1:800$ to phase I antigen by IFA or
  - *C. burnetii* nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen or
  - Histopathologic identification of *C. burnetii* antigen by IHC from a clinical specimen or
  - *C. burnetii* identified by culture from any clinical specimen
Critical Reporting Elements
Specify the clinical form of the disease. 
Document the source of infection if known. 
Document the circumstances under which the case patient was exposed including duty exposure, occupational activities, environmental exposures, or other high risk activities. 
Document any relevant travel and deployment history within the incubation period.

Comments
None.
Rabies, Human (*Lyssavirus*)

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th><em>Lyssavirus</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Present worldwide</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>An acute encephalomyelitis that almost always progresses to coma or death within 10 days after the first symptom.</td>
</tr>
</tbody>
</table>

**Case Classification**

**Confirmed:**

A case that meets the clinical description as described above with any of the following:

- Lyssavirus positive antigen by DFA from any clinical specimen (preferably the brain or nerves surrounding hair follicles in the nape of the neck) or
- Lyssavirus identified by culture from saliva or central nervous system tissue or
- Lyssavirus positive antibody by IFA or complete rabies virus neutralization at 1:5 dilution from CSF or
- Lyssavirus positive antibody by neutralization at 1:5 dilution from CSF of a vaccinated person or serum of an unvaccinated person or
- Lyssavirus nucleic acid (RNA) detected (example: PCR, sequencing, NAAT) in saliva, CSF, or tissue

**Critical Reporting Elements**

Specify the implicated animal species if known.

Document the circumstances under which the case patient was exposed including duty exposure, occupational activities, environmental exposures, or other high risk activities.

Note the patient’s rabies immunization history.

**Comments**

None.
## Relapsing Fever (Borrelia species)

**COMMON NAME:** Tick-borne relapsing fever (TBRF), louse-borne relapsing fever (LBRF)

### Background

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>Borrelia species (other than the Lyme disease agents)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>TBRF: Most common in Western United States, Western Europe, Middle East, Africa, and Central Asia</td>
</tr>
<tr>
<td></td>
<td>LBRF: Most common in sub-Saharan Africa and Andes region</td>
</tr>
</tbody>
</table>

| Clinical Description | An illness characterized by high fever, headache, muscle and joint aches, or nausea. Fever typically lasts 2 to 9 days and alternates with afebrile periods of 2 to 4 days. The total number of relapses varies from a single incident to over ten. |

### Case Classification

**Confirmed:**

A case that meets the clinical description as described above with any of the following:

- Microscopic identification of *Borrelia* from blood or
- *Borrelia* identified by intraperitoneal inoculation of laboratory rats or mice with blood or
- *Borrelia* identified by culture from blood

### Critical Reporting Elements

Document relevant travel and deployment history occurring within the incubation period. Document the circumstances under which the case patient was exposed including duty exposure, occupational activities, environmental exposures, or other high risk activities.

### Comments

None.

Last update: July 2017
# Rift Valley Fever (RVF)

## Background

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>Rift Valley fever virus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Most common in Africa and Saudi Arabia</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>An illness characterized by fever (may be biphasic), chills, headache, myalgia, or arthralgia. May include retinitis, encephalitis, and hemorrhage.</td>
</tr>
</tbody>
</table>

## Case Classification

**Confirmed:**

A case that meets the clinical description as described above with any of the following:

- RVF identified by culture from any clinical specimen or
- RVF positive antibody by PRNT from any clinical specimen or
- RVF positive antigen (example: EIA, ELISA) from any clinical specimen or
- RVF nucleic acid (RNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen or
- RVF positive IgM antibody from any clinical specimen or
- At least a four-fold change (increase or decrease) of IgG antibody titer between paired acute and convalescent sera

## Critical Reporting Elements

Document relevant travel and deployment history occurring within the incubation period.

Document the circumstances under which the case patient was exposed including duty exposure, occupational activities, environmental exposures, or other high risk activities.

## Comments

None.

Last update: July 2017
Rubella (rubella virus)

COMMON NAME: German measles

Background

Causative Agent  rubella virus
Travel Risks  Present worldwide
Clinical Description  An illness characterized by **ALL** of the following:
•  Acute onset of generalized maculopapular rash and
•  Temperature greater than 99.0°F or 37.2°C if measured and
•  Any of the following: arthralgia, arthritis, lymphadenopathy, or conjunctivitis

Case Classification

Suspect:
A case with any generalized rash illness of acute onset that does not meet the criteria for probable or confirmed rubella or any other illness

Probable:
In the absence of a more likely diagnosis, a case that meets the clinical description as described above with **ALL** of the following:
•  Lack of epidemiologic linkage to a laboratory-confirmed case of rubella and
•  Noncontributory or no serologic or virologic test performed

Confirmed:
A case that meets any of the following:
•  Rubella identified by culture from any clinical specimen or
•  Rubella nucleic acid (RNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen or
•  Seroconversion† from a negative IgG followed by a positive IgG or
•  Significant rise of an IgG antibody titer between acute and convalescent sera or
•  Rubella positive IgM antibody†* from serum or
•  A case meeting the clinical description as described above that is epidemiologically linked to a confirmed case

Critical Reporting Elements

Specify whether the patient presented with congenital rubella syndrome or whether the patient is pregnant.
Document relevant travel and deployment history occurring within the incubation period.
Note the patient’s rubella immunization history.

Comments

Patients who have laboratory evidence of recent measles infection are excluded.
† Not explained by MMR vaccination during the previous 6-45 days.
*Not otherwise ruled out by more specific testing in a public health laboratory.

Last update: July 2017
**Salmonellosis (Salmonella species)**

INCLUDES: *Salmonella* species, including *Salmonella* Paratyphi

EXCLUDES: *Salmonella* Typhi. See Typhoid Fever case definition.

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th><em>Salmonella</em> species</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>N/A</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>An illness of variable severity commonly manifested by diarrhea, abdominal pain, nausea, and sometimes vomiting.</td>
</tr>
</tbody>
</table>

**Case Classification**

**Probable:**

Any of the following:

- *Salmonella* positive laboratory test by a method other than culture (example: EIA, PCR) from any clinical specimen or
- A case that meets the clinical description as described above that is epidemiologically linked to a probable or a confirmed case

**Confirmed:**

*Salmonella* identified from culture from any clinical specimen

**Critical Reporting Elements**

Specify the serotype characterization (O and H antigen) if known.

Document if the case patient works in, lives in, or attends a high transmission setting such as food handling, day care, school, group living, healthcare, training center, or ship.

**Comments**

None.
# Schistosomiasis (Schistosoma species)

## Background

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th><em>Schistosoma</em> species. Most human infections are caused by <em>Schistosoma mansoni</em>, <em>Schistosoma haematobium</em>, or <em>Schistosoma japonicum</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Most common in Africa, the Middle East, South America, Indonesia, some parts of China, and Southeast Asia</td>
</tr>
<tr>
<td>Clinical Description</td>
<td><strong>Urinary schistosomiasis:</strong> gives rise to dysuria, frequency, and hematuria at the end of urination, and is usually caused by <em>Schistosoma haematobium</em>.</td>
</tr>
<tr>
<td></td>
<td><strong>Intestinal schistosomiasis:</strong> is normally accompanied by diarrhea, abdominal pain, and hepatosplenomegaly, and is caused by <em>Schistosoma mansoni</em> and <em>Schistosoma japonicum</em>.</td>
</tr>
</tbody>
</table>

## Case Classification

**Confirmed:**
A case that meets the clinical description as described above with microscopic identification of eggs from stool, urine or biopsy specimens

## Critical Reporting Elements

Specify the clinical form of the disease.
Document relevant travel and deployment history occurring within the incubation period.
Document the circumstances under which the case patient was exposed including duty exposure, occupational activities, environmental exposures, or other high risk activities.

## Comments
None.

Last update: July 2017
Severe Acute Respiratory Syndrome (SARS)

COMMON NAME: SARS

INCLUDES: SARS-CoV-1


Background

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>SARS-CoV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Present worldwide</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>SARS is characterized by severity of illness as follows:</td>
</tr>
<tr>
<td></td>
<td>Early illness: Two or more of the following:</td>
</tr>
<tr>
<td></td>
<td>Fever (might be subjective), chills, rigors, myalgia, headache, diarrhea, sore throat, or rhinorhea.</td>
</tr>
<tr>
<td></td>
<td>Mild-to-moderate respiratory illness: Temperature of &gt; 100.4°F (&gt; 38°C) and one or more clinical findings of lower respiratory illness (example: cough, shortness of breath, or difficulty breathing).</td>
</tr>
<tr>
<td></td>
<td>Severe respiratory illness: Meets clinical description for mild-to-moderate respiratory illness with any of the following:</td>
</tr>
<tr>
<td></td>
<td>• Radiographic evidence of pneumonia or</td>
</tr>
<tr>
<td></td>
<td>• Acute respiratory distress syndrome</td>
</tr>
</tbody>
</table>

Case Classification

**Suspect:**
A case that meets the clinical case description for mild-to-moderate respiratory illness as described above and exposure criteria* is met as described below

**Probable:**
A case that meets the clinical description for severe respiratory illness as described above and exposure criteria* is met as described below.

**Confirmed:**
A case that meets any of the clinical case descriptions as described above with any of the following:
- SARS-CoV positive antibody (example: EIA) from serum or
- SARS-CoV identified by culture from any clinical specimen or
- SARS-CoV nucleic acid (RNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen and with subsequent confirmation in a reference laboratory (example: DoD or CDC)

Critical Reporting Elements
Document relevant travel and deployment history occurring within the incubation period.

Comments

*Exposure is defined as one or more of the following in the 10 days before onset of symptoms:
• Close contact as defined in the definition page with a person with confirmed SARS-CoV disease
  or
• Close contact as defined in the definition page with a person with mild-to-moderate or severe
  respiratory illness for whom a chain of transmission can be linked to a confirmed case of SARS-
  CoV disease

A person can be excluded as a reportable case of SARS if any of the following apply:
• An alternative diagnosis can fully explain the illness or
• Antibody to SARS-CoV is undetectable in a serum specimen obtained > 28 days after onset of
  illness or
• The case was reported on the basis of contact with a person who was excluded subsequently as
  a case of SARS-CoV disease; then the reported case also is excluded, provided other
  epidemiologic or laboratory criteria are not present

Last update: July 2017
**Shigellosis (Shigella species)**

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th><em>Shigella</em> species</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>N/A</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>An illness of variable severity characterized by diarrhea, fever, nausea, cramps, and tenesmus. Asymptomatic infections may occur.</td>
</tr>
</tbody>
</table>

**Case Classification**

**Suspect:**
A case with an undifferentiated *Shigella*/enteroinvasive *E. coli* (EIEC) positive laboratory test by a method other than culture (example: EIA, PCR) from any clinical specimen

**Probable:**
A case that meets any of the following:
- *Shigella* positive laboratory test by a method other than culture (example: EIA, PCR) from any clinical specimen or
- A case that meets the clinical description as described above that is epidemiologically linked to a probable or confirmed case

**Confirmed:**
*Shigella* identified by culture from any clinical specimen

**Critical Reporting Elements**
Specify the serotype characterization (O antigen) if known.
Document the source of infection if known.
Document if the case patient works in, lives in, or attends a high transmission setting such as food handling, day care, school, group living, healthcare, training center, or ship.

**Comments**
Identification of Shiga toxin is presumptive for Shiga toxin-producing *E. coli* (STEC) and should not be reported as Shigellosis.

Last update: January 2020
Smallpox (variola virus)

EXCLUDES: Vaccinations and vaccine adverse events

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>variola virus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>N/A</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>An illness with acute onset of fever ≥ 101°F (≥ 38.3°C) followed by a rash characterized by firm, deep seated vesicles or pustules in the same stage of development without other apparent cause.</td>
</tr>
<tr>
<td>Clinically Consistent</td>
<td>Clinically consistent cases are those presentations of smallpox that do not meet the classical clinical description and include: a) hemorrhagic type, b) flat type, and c) variola sine eruptione.</td>
</tr>
</tbody>
</table>

**Case Classification**

**Suspect:**
A case with a generalized acute vesicular or pustular rash illness with a fever that precedes the rash by 1-4 days

**Probable:**
A case with any of the following:
- A case that meets the clinical description as described above or
- A clinically consistent case as described above that is epidemiologically linked to a confirmed case

**Confirmed:**
A case with any of the following:
- Smallpox nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) that was performed from culture from any clinical specimen or
- Smallpox identified by culture from any clinical specimen tested only in a Level D laboratory or
- A case that meets the clinical case description as described above that is epidemiologically linked to a confirmed case

**Critical Reporting Elements**

Document the source of infection if known.
Document the circumstances under which the case patient was exposed including duty exposure, occupational activities, environmental exposures, or other high risk activities.

**Comments**
None.

Last update: July 2017
Spotted Fever Rickettsiosis (*Rickettsia* species)

INCLUDES: Rocky Mountain spotted fever, Pacific Coast tick fever, African tick-bite fever, and others

EXCLUDES: *Rickettsia prowazekii* and *Rickettsia typhi*. See Typhus Fever case definition.

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>Rickettsia species</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Present worldwide</td>
</tr>
</tbody>
</table>

Spotted Fever group *Rickettsiae* (SFGR) are illness characterized by fever (reported by the patient or provider) and one or more of the following: rash, eschar, headache, myalgia, anemia, thrombocytopenia, or any hepatic transaminase elevation (AST or ALT). The macular or maculopapular rash appears on the fourth to seventh days following fever onset in most patients, often present on the palms and soles. Most often tick-borne, but some *Rickettsia* species can be transmitted by mites and fleas.

**Case Classification**

**Suspect:**

A case with any of the following:

- A case that meets the clinical description as described above with an elevated SFGR IgG antibody titer of < 1:128 by IFA in a sample taken within 60 days of illness onset or
- A case with no clinical information available and any of the following:
  - Elevated SFGR IgG antibody titer of ≥ 1:128 by IFA in a sample taken within 60 days of illness onset* or
  - At least a four-fold increase of IgG antibody titer by IFA between paired acute and convalescent sera (one taken in the first two weeks of illness and a second taken 2-10 weeks later) ‡ or
  - SFGR nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) using a genus- or species-specific target from any clinical specimen or
  - SFGR nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from the cell culture of any clinical specimen or
  - Histopathologic identification of SFGR antigens by IHC from a biopsy or autopsy specimen

**Probable:**

A case that meets the clinical description as described above with the following:

- SFGR positive IgG antibody titer ≥ 1:128 by IFA in a sample taken within 60 days of illness onset*

**Confirmed:**

A case that meets the clinical description as described above with any of the following:

- At least a four-fold increase in SFGR IgG antibody titer by IFA between paired acute and convalescent sera (one taken in the first two weeks of illness and a second taken 2-10 weeks later) ‡ or
- SFGR nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) using a *Rickettsia* genus- or species-specific target from any clinical specimen or
• SFGR nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from the cell culture of any clinical specimen
• Histopathologic identification of SFGR antigen by IHC from a biopsy or autopsy specimen or

Critical Reporting Elements
Document relevant travel and deployment history occurring within the 14 days prior to symptom onset. Document potential occupational/high risk exposure (outdoor activity, camping, hunting, field exercise, mission/duty related, etc.) to known arthropods.

Comments
There can be antibody cross-reactivity between spotted fever and typhus group antigens. In cases where antibody titers are positive for both diseases, report the case under the disease most consistent with the case’s clinical presentation, exposure history, and travel history.

*This includes paired serum specimens without evidence of four-fold rise in titer, but with at least one single titer ≥1:128 in IgG-specific antibody titers reactive with SFGR antigen by IFA.
‡ A four-fold rise in titer should not be excluded as confirmatory laboratory criteria if the acute and convalescent specimens are collected within two weeks of one another.

A person previously reported as a probable or confirmed case may be reported as a new case when there is an episode of new clinically compatible illness with confirmatory laboratory evidence.
**Syphilis (Treponema pallidum)**

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>Treponema pallidum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>N/A</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>Syphilis is a systemic, sexually transmitted infection that can cause a variety of clinical manifestations if untreated. The disease course is complex and variable. For surveillance purposes, syphilis is characterized by a combination of 1) clinical signs and 2) time since infection. Stage of infection reflects both, and case reporting should include both the stage and any specific clinical manifestations.</td>
</tr>
</tbody>
</table>

**Clinical Description**

**Stage of infection:**

**Primary:** One or more painless ulcerative lesions (chancres). Lesions are typically on the genitals, in the rectal area or in the mouth, and because they are painless, the patient may not be aware of them. Careful and thorough clinical examination is required.

**Secondary:** A rash, often including the palms and soles of the feet, with swollen lymph nodes. Other symptoms can include mucous patches, wart like genital lesions, and hair loss. The primary ulcerative lesion may still be present.

**Early latent (early non-primary non-secondary):** Asymptomatic, infected in the last 12 months.

**Late/Tertiary/Unknown:** A case infected more than 12 months ago. Neurological findings usually predominate such as dementia and gait disturbances (tabes dorsalis). Clinical findings may also include many other systemic findings to include gummas (syphilitic growths on organs and skin), eye or ear involvement that can result in blindness or hearing loss, and variable involvement of other organ systems. Clinical symptoms may occur decades after an untreated initial infection.

**Congenital:** Fetal infection with *T. pallidum* can result in a broad range of severity in infants, from inapparent infection to severe abnormalities and stillbirth.

**Case Classification**

**Primary:**

**Probable:** A case that meets the clinical description of primary syphilis as described above with any of the following:

- Reactive nontreponemal tests by VDRL, Reagin (RPR), or equivalent serological methods or
- Reactive treponemal specific tests by FTA-ABS, TP-PA, EIA, CIA, or equivalent serological methods

Last update: January 2022
**Confirmed:**
A case that meets the clinical description of primary syphilis as described above with any of the following:
- Microscopic identification of *T. pallidum* by dark field microscopy from any clinical specimen or
- *T. pallidum* nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen

**Secondary:**
**Probable:**
A case that meets the clinical description of secondary syphilis as described above with **ALL** of the following:
- Reactive nontreponemal tests by VDRL, Reagin (RPR), or equivalent serological methods and
- Reactive treponemal specific tests by FTA-ABS, TP-PA, EIA, CIA, or equivalent serological methods

**Confirmed:**
A case that meets the clinical description of secondary syphilis as described above with any of the following:
- Microscopic identification of *T. pallidum* by dark field microscopy from any clinical specimen or
- *T. pallidum* nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen

**Early Latent (early non-primary non-secondary):**
**Probable:**
An asymptomatic case with **ALL** of the following:
- Infection was acquired within the past 12 months* and
- No prior history of syphilis and
- A reactive nontreponemal test by VDRL, Reagin (RPR), or equivalent serologic methods and
- A reactive treponemal specific test by FTA-ABS, TP-PA, EIA, CIA, or equivalent serologic methods

OR

An asymptomatic case with **ALL** of the following:
- Infection was acquired within the past 12 months* and
- A prior history of syphilis and
- A nontreponemal test titer by VDRL, Reagin (RPR), or equivalent serologic methods demonstrating at least a four-fold increase from the last nontreponemal test titer

**Late/Tertiary/Unknown:**
**Probable:**
An asymptomatic case with **ALL** of the following:
- Infection was acquired more than 12 months ago and
- No prior history of syphilis and
- A reactive nontreponemal test by VDRL, Reagin (RPR), or equivalent serologic methods and
- A reactive treponemal specific test by FTA-ABS, TP-PA, EIA, CIA, or equivalent serologic methods

OR

An asymptomatic case with **ALL** of the following:
- Infection was acquired more than 12 months ago and
- A prior history of syphilis and
- A nontreponemal test titer by VDRL, Reagin (RPR), or equivalent serologic methods demonstrating at least a four-fold increase from the last nontreponemal test titer

OR

A case that meets the clinical description of late/tertiary/unknown syphilis as described above and infection was acquired more than 12 months ago.

**Congenital:**

**Probable:**
An infant or child less than 2 years of age whose mother had untreated or inadequately treated syphilis at delivery

OR

An infant or child less than 2 years of age with a reactive nontreponemal test by VDRL, Reagin (RPR), or equivalent method and any of the following:
- Meets the clinical description of congenital syphilis as described above or
- Evidence of congenital syphilis on radiographs of long bones or
- Positive VDRL test from cerebrospinal fluid (CSF) or
- Elevated cerebrospinal fluid (CSF) white blood cell count or protein without other cause in a non-traumatic lumbar puncture

**Confirmed:**
An infant or child less than 2 years of age with any of the following:
- Microscopic identification of *T. pallidum* by dark field microscopy from lesions, body fluids, or neonatal nasal discharge or
- *T. pallidum* nucleic acid detected (example: PCR, sequencing, NAAT) from lesions, neonatal nasal discharge, placenta, umbilical cord, or autopsy material or
- Microscopic identification of *T. pallidum* by IHC or special stains from lesions, placenta, umbilical cord, or autopsy material

**Critical Reporting Elements**
Specify the stage of the disease and any diagnosed clinical manifestation.

**Comments**
Neuro, ocular, and otic manifestations can occur at any stage of disease.
There is no confirmed case classification for early latent (early non-primary non-secondary) syphilis.

Last update: Nov 2021
The following are acceptable as evidence of having acquired syphilis within the preceding 12 months:

- Seroconversion from a negative nontreponemal test by VDRL, Reagin (RPR), or equivalent serologic methods followed by a positive nontreponemal test during the previous 12 months or
- A nontreponemal test titer by VDRL, Reagin (RPR), or equivalent serologic methods demonstrating at least a four-fold increase from the last nontreponemal test titer during the previous 12 months or
- Seroconversion from a negative treponemal specific test by FTA-ABS, TP-PA, EIA, CIA, or equivalent serological methods followed by a positive treponemal specific test during the previous 12 months or
- A history of symptoms consistent with the clinical description of primary or secondary syphilis during the previous 12 months or
- A history of sexual exposure to a partner within the previous 12 months who had primary, secondary, or early latent syphilis with a duration of less than 12 months or
- Only sexual contact (1st sexual encounter) was within the last 12 months

**Symptoms of primary syphilis:**
- Early syphilis: A rash, often including the palms and soles of the feet, with swollen lymph nodes. Other symptoms can include mucous patches, wart-like genital lesions, and hair loss. The primary ulcerative lesion may still be present.

**Symptoms of secondary syphilis:**
- Asymptomatic
- Acquired within past 12 months: Report as probable
- Acquired more than 12 months ago: Late/Tertiary/Unknown: Report as probable

**Symptoms of late/Tertiary/unknown syphilis:**
- NO LAB RESULTS

NOTE: Most cases of syphilis will only be reportable as probable. To be confirmed, there needs to be a positive nucleic acid/PCR test or microscopy.

*Symptoms of primary syphilis: One or more painless ulcerative lesions (chancres). Lesions are typically on the genitals, in the rectal area or in the mouth, and because they are painless, the patient may not be aware of them. Careful and thorough clinical examination is required.

**Symptoms of secondary syphilis: A rash, often including the palms and soles of the feet, with swollen lymph nodes. Other symptoms can include mucous patches, wart-like genital lesions, and hair loss. The primary ulcerative lesion may still be present.
### Tetanus (Clostridium tetani)

**COMMON NAME:** Lockjaw

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>Clostridium tetani</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Present worldwide</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>An illness characterized by acute onset of hypertonia or painful muscular contractions (usually the jaw and neck) and generalized muscle spasms without other apparent medical cause.</td>
</tr>
</tbody>
</table>

**Case Classification**

**Probable:**
In the absence of a more likely diagnosis, a case that meets the clinical description as described above with a diagnosis of tetanus by a health care provider.

**Critical Reporting Elements**

Note the patient’s tetanus immunization history.

**Comments**

There is no confirmed case classification for tetanus.

Last update: July 2017
**Toxic Shock Syndrome (TSS)**

INCLUDES: Streptococcal TSS and non-streptococcal TSS

**Background**

| Causative Agent | Streptococcal TSS: *Streptococcus pyogenes* (Group A Strep)  
Non-streptococcal: Often caused by *Staphylococcus aureus*  
Travel Risks | N/A  
Clinical Description |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Streptococcal TSS:</strong></td>
<td></td>
</tr>
</tbody>
</table>
- Hypotension defined by a systolic blood pressure less than or equal to 90 mm Hg for adults or less than the fifth percentile by age for children aged less than 16 years  
- Multi-organ involvement characterized by two or more of the following:  
  - Renal impairment: Creatinine greater than or equal to 2 mg/dL (greater than or equal to 177 µmol/L) for adults or greater than or equal to twice the upper limit of normal for age. In patients with preexisting renal disease, a greater than twofold elevation over the baseline level.  
  - Coagulopathy: Platelets less than or equal to 100,000/mm³ (less than or equal to 100 x 10⁶/L) or disseminated intravascular coagulation, defined by prolonged clotting times, low fibrinogen level, and the presence of fibrin degradation products  
  - Liver involvement: Alanine aminotransferase, aspartate aminotransferase, or total bilirubin levels greater than or equal to twice the upper limit of normal for the patient's age. In patients with preexisting liver disease, a greater than twofold increase over the baseline level  
  - Acute respiratory distress syndrome: defined by acute onset of diffuse pulmonary infiltrates and hypoxemia in the absence of cardiac failure or by evidence of diffuse capillary leak manifested by acute onset of generalized edema, or pleural or peritoneal effusions with hypoalbuminemia  
  - A generalized erythematous macular rash that may desquamate  
  - Soft-tissue necrosis, including necrotizing fasciitis or myositis, or gangrene  
| **Non-streptococcal TSS:** |  
- Fever: temperature greater than or equal to 102.0°F (greater than or equal to 38.9°C)  
- Rash: diffuse macular erythroderma  
- Desquamation: 1-2 weeks after onset of rash  
- Hypotension: systolic blood pressure less than or equal to 90 mm Hg for adults or less than fifth percentile by age for children aged less than 16 years  
- Multisystem involvement (three or more of the following organ systems):  
  - Gastrointestinal: vomiting or diarrhea at onset of illness  
  - Muscular: severe myalgia or creatine phosphokinase level at least twice the upper limit of normal
Mucous membrane: vaginal, oropharyngeal, or conjunctival hyperemia
Renal: blood urea nitrogen or creatinine at least twice the upper limit of normal for laboratory or urinary sediment with pyuria (greater than or equal to 5 leukocytes per high-power field) in the absence of urinary tract infection
Hepatic: total bilirubin, alanine aminotransferase enzyme, or aspartate aminotransferase enzyme levels at least twice the upper limit of normal for laboratory
Hematologic: platelets less than 100,000/mm³
Central nervous system: disorientation or alterations in consciousness without focal neurologic signs when fever and hypotension are absent

Case Classification

**Streptococcal TSS:**

**Probable:**
A case that meets the clinical description of Streptococcal TSS as described above with **ALL** of the following:
- Group A *Streptococcus* (*S. pyogenes*) identified by culture from a non-sterile site and
- There is no other identified cause for the illness

**Confirmed:**
A case that meets the clinical description of Streptococcal TSS as described above with the following:
- Group A *Streptococcus* (*S. pyogenes*) identified by culture from a normally sterile site (example: blood or CSF or, less commonly, joint, pleural, or pericardial fluid)

**Non-streptococcal TSS:**

**Probable:**
A case that has four of the five criteria listed in the clinical description of non-streptococcal TSS as described above with **ALL** of the following:
- Negative culture, if obtained, from blood or CSF (blood culture may be positive for *Staphylococcus aureus*) and
- Negative serologies, if obtained, for Rocky Mountain spotted fever, leptospirosis, or measles

**Confirmed:**
A case that meets all five criteria of the clinical description of non-streptococcal TSS as described above with **ALL** of the following:
- Negative culture, if obtained, from blood or CSF (blood culture may be positive for *Staphylococcus aureus*) and
- Negative serologies, if obtained, for Rocky Mountain spotted fever, leptospirosis, or measles and
- Desquamation must be present unless the patient dies before desquamation occurs

**Critical Reporting Elements**
Specify the clinical form of the disease.

**Comments**
None.

Last update: July 2017
Trichinellosis (*Trichinella* species)

**COMMON NAME:** Trichinosis

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th><em>Trichinella</em> species</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Present worldwide</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>The disease has variable clinical manifestations. Common signs and symptoms among symptomatic persons include eosinophilia, fever, myalgia, and periorbital edema.</td>
</tr>
</tbody>
</table>

**Case Classification**

**Suspect:**
A case that meets **ALL** of the following:
- A person who ate epidemiologically implicated food and
- *Trichinella* positive serologic test and
- Has no known prior history of *Trichinella* infection

**Probable:**
A case that meets the clinical description as described above with any of the following:
- A person who ate epidemiologically implicated food or
- A person who consumed a meat product in which *Trichinella* was demonstrated

**Confirmed:**
A case that meets the clinical description as described above with any of the following:
- *Trichinella* larvae identified from tissue biopsy or
- *Trichinella* positive serologic test

**Critical Reporting Elements**
Document the source of infection if known.

**Comments**

*Trichomonas* and trichomoniasis are STDs and are not the same thing as Trichinellosis. *Trichomonas* and trichomoniasis are not reportable and should not be reported as Trichinellosis. Epidemiologically implicated food is defined as food that was consumed by a person who subsequently became a confirmed case.

Last update: July 2017
## Trypanosomiasis (*Trypanosoma* species)

| COMMON NAME: | African trypanosomiasis: Sleeping sickness  
|             | American trypanosomiasis: Chagas disease |

### Background

**Causative Agent**

- African trypanosomiasis: *Trypanosoma brucei* (*T.b. rhodesiense* and *T. b. gambiense*)
- American trypanosomiasis: *Trypanosoma cruzi*

**Travel Risks**

- African trypanosomiasis: Most common in rural sub-Saharan Africa
- American trypanosomiasis: Most common in Mexico, Central America, and South America

**Clinical Description**

**African Trypanosomiasis:** In the early stages of infection, there may be a painful chancre, which originates as a papule and evolves into a nodule at the site of the tsetse fly bite. There may be fever, intense headache, insomnia, painless swollen lymph nodes, anemia, local edema and rash. In the later stages, there may be cachexia, central nervous system dysfunction, and somnolence (hence the name “sleeping sickness”). The disease may run a protracted course of several years in the case of *T. b. gambiense*. In cases of *T. b. rhodesiense*, the disease has a rapid and acute evolution. Disease caused by either species is always fatal without treatment.

**Acute American Trypanosomiasis:** Acute disease occurs immediately after infection and may last up to a few weeks or months. Infections may be mild or asymptomatic. If symptoms do develop, they are typically mild or nonspecific, and include fever, malaise, and hepatosplenomegaly. An inflammatory response at the infection site (chagoma) may last several weeks.

**Chronic American Trypanosomiasis:** Most infected people enter into a prolonged asymptomatic form of disease (“chronic indeterminate”) following the acute phase. Many remain asymptomatic for life. Approximately 20-30% of chronic American trypanosomiasis cases develop severe symptoms including cardiovascular complications (heart rhythm abnormalities, dilated heart) or gastrointestinal complications (dilated esophagus or colon, leading to difficulties eating or passing stool).

### Case Classification

**African Trypanosomiasis:**

**Suspect:**
A case that meets the clinical description of African Trypanosomiasis as described above with travel to an endemic area

**Probable:**
A provider diagnosed case with any of the following:
- *T. b. gambiense* positive by CATT or
- *T. b. rhodesiense* or *T. b. gambiense* positive by IFA
**Confirmed:**
A case with microscopic identification of trypanosomes from blood, lymph node aspirates, or CSF

**American Trypanosomiasis:**

**Probable:**
A case with any of the following:
- *T. cruzi* positive blood screening test and a positive supplemental test (example: EIA, IFA, TESA, RIPA) from serum or
- Provider diagnosis of Chagas disease and *T. cruzi* positive antibody on at least one diagnostic assay

**Confirmed:**
A case with any of the following:
- Microscopic identification of *T. cruzi* (microscopic examination, wet mount, thick & thin smears - Giemsa stain) or
- *T. cruzi* identified by culture or
- *T. cruzi* nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) or
- *T. cruzi* positive antibody by two distinct diagnostic assays performed at CDC

**Critical Reporting Elements**
Specify the form of disease.
Document relevant travel and deployment history occurring within the incubation period.
Specify whether the patient presented with congenital disease.

**Comments**
None.

Last update: January 2020
**Tuberculosis (Mycobacterium tuberculosis)**

**COMMON NAME:** TB

**INCLUDES:** Pulmonary and non-pulmonary Tuberculosis

**EXCLUDES:** Latent tuberculosis infection (LTBI) when a person tests positive via Mantoux tuberculin skin test (TST) or via FDA approved interferon-gamma release assay (IGRA) but is without evidence of active disease (negative chest x-ray for presence of TB disease and asymptomatic).

**Background**

**Causative Agent**

*Mycobacterium tuberculosis*

**Travel Risks**

Present worldwide

**Clinical Description**

An illness characterized by acute history of persistent cough, pain or tightness in the chest, bloody sputum, weakness or fatigue, weight loss, loss of appetite, chills, fever, or night sweats. The most common site of infection is the lung though other organs can be involved.

**Case Classification**

**Suspect:**

A case that meets the clinical description as described above with imaging studies compatible with tuberculosis

**Confirmed:**

A case with any of the following:

- *M. tuberculosis* identified by culture from any clinical specimen* or
- *M. tuberculosis* nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen or
- Microscopic identification of acid-fast bacilli from any clinical specimen when a culture has not been or cannot be obtained or
- A provider-diagnosed case with **ALL** of the following:
  - A positive TST or positive IGRA for *M. tuberculosis* and
  - Other signs and symptoms compatible with tuberculosis (example: abnormal chest radiograph, abnormal chest computerized tomography scan or other chest imaging study, or clinical evidence of current disease) and
  - Treatment with two or more anti-TB medications and
  - A completed diagnostic evaluation

**Critical Reporting Elements**

Document the circumstances under which the case patient was exposed including duty exposure, occupational activities, environmental exposures, or other high risk activities. Document if the case patient works in, lives in, or attends a high transmission setting such as food handling, day care, school, group living, healthcare, training center, or ship. Note the patient’s BCG (tuberculosis vaccine) immunization history. Document evidence of drug resistance.
Comments

*Use of a rapid test (example: DNA probe, liquid chromatography) performed from the culture is acceptable for this criteria.

Last update: January 2020
Tularemia (*Francisella tularensis*)

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th><em>Francisella tularensis</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Most common in North America and in parts of Europe, Russia, China, and Japan</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>An illness characterized by several distinct forms, including the following:</td>
</tr>
<tr>
<td></td>
<td><strong>Ulceroglandular:</strong> cutaneous ulcer with regional swollen lymph nodes</td>
</tr>
<tr>
<td></td>
<td><strong>Glandular:</strong> regional swollen lymph nodes with no ulcer</td>
</tr>
<tr>
<td></td>
<td><strong>Oculoglandular:</strong> conjunctivitis with preauricular swollen lymph nodes</td>
</tr>
<tr>
<td></td>
<td><strong>Oropharyngeal:</strong> stomatitis or pharyngitis or tonsillitis and cervical swollen lymph nodes</td>
</tr>
<tr>
<td></td>
<td><strong>Intestinal:</strong> intestinal pain, vomiting, and diarrhea</td>
</tr>
<tr>
<td></td>
<td><strong>Pneumonic:</strong> primary pleuropulmonary disease</td>
</tr>
<tr>
<td></td>
<td><strong>Typhoidal:</strong> febrile illness without early localizing signs and symptoms</td>
</tr>
</tbody>
</table>

**Case Classification**

**Probable:**

A case that meets any of the clinical descriptions as described above with any of the following:

- *F. tularensis* positive antibody titer in a patient without a history of tularemia vaccination from any clinical specimen or
- *F. tularensis* positive fluorescent assay from any clinical specimen or
- *F. tularensis* nucleic acid (RNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen

**Confirmed:**

A case that meets any of the clinical descriptions as described above with any of the following:

- *F. tularensis* identified by culture from any clinical specimen or
- At least a four-fold change (increase or decrease) of antibody titer between paired acute and convalescent sera

**Critical Reporting Elements**

Specify the clinical form of the disease.

Document the circumstances under which the case patient was exposed including duty exposure, occupational activities, environmental exposures, or other high risk activities.

**Comments**

None.

Last update: July 2017
Typhoid Fever (*Salmonella enterica* serovar Typhi)

**COMMON NAME:** *Salmonella* Typhi, enteric fever

**EXCLUDES:** All other *Salmonella* species including *Salmonella Typhimurium*. See *Salmonella* case definition.

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th><em>Salmonella enterica</em> serotype Typhi (<em>S. Typhi</em>)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Most common in Southern Asia, East and Southeast Asia, Africa, the Caribbean, and Central and South America</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>An illness often characterized by insidious onset of sustained fever, headache, malaise, anorexia, slow heart rate, constipation or diarrhea, and nonproductive cough. However, many mild and atypical infections occur. Carriage of <em>S. Typhi</em> may be prolonged.</td>
</tr>
</tbody>
</table>

**Case Classification**

**Probable:**
A case that meets the clinical description as described above that is epidemiologically linked to a confirmed case in an outbreak

**Confirmed:**
A case that meets the clinical description as described above with *S. Typhi* identified by culture from any clinical specimen

**Critical Reporting Elements**
Document relevant travel and deployment history occurring within the incubation period.
Note the patient’s typhoid immunization history.

**Comments**
*Salmonella* Typhi and *Salmonella Typhimurium* are not the same organisms. *Salmonella Typhimurium* is reportable under *Salmonella*.

The only time a case should be reported as probable is during an outbreak.

Last update: July 2017
**Typhus Fever** (*Rickettsia prowazekii, Rickettsia typhi, or Orientia tsutsugamushi*)

**EXCLUDES:** All other *Rickettsia* species. See spotted fever rickettsiosis case definition.

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th><em>Rickettsia prowazekii, Rickettsia typhi, or Orientia tsutsugamushi</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Specific to each presentation. See the clinical description for distributions.</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>A group of arthropod-borne diseases with three clinically distinct presentations, each with its own specific infectious agent and vector:</td>
</tr>
</tbody>
</table>

**Epidemic (Louse-borne) Typhus:** (*Rickettsia prowazekii*) An illness characterized by any reported fever and one or more of the following: rash, headache, chills, prostration, and general pain. The macular or maculopapular rash appears on the fifth to sixth day, initially on the upper trunk followed by spread to the entire body, but usually sparing the face, palm, and soles. The infectious agent is transmitted by body lice. Most commonly found in the colder (i.e., mountainous) regions of central and eastern Africa, Central and South America, and Asia. In the United States, rare cases of epidemic typhus, called sylvatic typhus, can occur after exposure to flying squirrels and their nests.

**Murine (Endemic) Typhus:** (*Rickettsia typhi*) Similar to louse-borne typhus, but often milder. The infectious agent is transmitted by fleas. Endemic in Mediterranean countries, some African, Central American, and South American countries, some coastal states in the USA, and Southeast Asia.

**Scrub Typhus:** (*Orientia tsutsugamushi*) Often produces a primary “punched out” skin eschar corresponding to the primary attachment of an infected mite. Acute onset of symptoms follows within several days, characterized by fever, headache, profuse sweating, conjunctival injection and lymphadenopathy. A dull red maculopapular eruption appears on the trunk late in the first week, gradually extending to the extremities. Endemic to Southeast Asia, Indonesia, China, Japan, India, and northern Australia.

**Case Classification**

**R. prowazekii or R. typhi**

**Probable:**
A case that meets the clinical description as described above with the following:

- *R. prowazekii* or *R. typhi* (typhus fever group) positive IgM or IgG antibody titer by IFA, ELISA, or latex agglutination from serum

**Confirmed:**
A case that meets the clinical description as described above with any of the following:

- At least a four-fold change (increase or decrease) in antibody titer by IFA, CF, LA, MAT, or IHA between paired acute and convalescent sera separated by at least 3 weeks or
- *R. prowazekii* or *R. typhi* nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen or
• Histopathologic identification of *R. prowazekii* or *R. typhi* antigen by IHC from skin lesion (biopsy) or organ tissue (autopsy) or
• *R. prowazekii* or *R. typhi* positive antigen by IFA or DFA from skin lesions or
• *R. prowazekii* or *R. typhi* identified by culture from any clinical specimen

**O. tsutsugamushi**

**Confirmed:**
A case that meets the clinical description as described above with any of the following:
• *O. tsutsugamushi* identified from culture by inoculation of patient blood in white mice (preferably treated with cyclophosphamide at 0.2mg/g intraperitoneally or intramuscularly on days 1, 2 and 4 after inoculation) or
• *O. tsutsugamushi* positive IgM antibody by IFA, Weil-Felix agglutination from serum

**Critical Reporting Elements**
Specify the clinical form of the disease.
Document relevant travel and deployment history occurring within the 14 days prior to symptom onset.
Document the circumstances under which the case patient was exposed including duty exposure, occupational activities, environmental exposures, or other high risk activities.

**Comments**
There can be antibody cross-reactivity between spotted fever and typhus group antigens. In cases where IgM or IgG titers are positive for both diseases, report the case under the disease most consistent with the case’s clinical presentation, exposure history, and travel history.

Last update: January 2020
Varicella (varicella-zoster virus)

COMMON NAME: Chickenpox (varicella virus)

EXCLUDES: Shingles (zoster virus, herpes zoster virus)

Background

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>Varicella-zoster virus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>N/A</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>Acute onset of diffuse (generalized) maculo-papulovesicular rash without other apparent cause.</td>
</tr>
</tbody>
</table>

Case Classification

Probable:
A case that meets the clinical description as described above where lab results are not available and there is no epidemiologic link to a probable or confirmed case.

Confirmed:
A case that meets the clinical description as described above with any of the following:

- Epidemiologically linked to a probable or confirmed case or
- Varicella identified by culture from any clinical specimen or
- Varicella positive antigen by DFA from any clinical specimen or
- Varicella nucleic acid (DNA) detected (example: PCR, sequencing, NAAT) from any clinical specimen or
- At least a one-fold increase of IgG antibody titer between acute and convalescent sera

OR

Two probable cases that are epidemiologically linked

Critical Reporting Elements

Document if the case patient works in, lives in, or attends a high transmission setting such as food handling, day care, school, group living, healthcare, training center, or ship.
Note the patient’s varicella immunization history.

Comments

NOTE: This case definition includes all beneficiaries and is no longer limited to only Active Duty service members.

Last update: January 2020
Yellow Fever (yellow fever virus)

Background

Causative Agent: yellow fever virus
Travel Risks: Most common in subtropical areas of South America and Africa
Clinical Description: An acute illness, in the absence of a more likely clinical explanation, with at least one of the following:
- Fever or
- Jaundice or
- Elevated total bilirubin ≥ 3.0 mg/dl

Case Classification

Probable:
A case that meets the clinical description as described above with ALL of the following:
- Yellow fever virus-specific IgM antibodies in CSF or serum and
- Negative IgM antibodies for other arboviruses endemic to the region where exposure occurred and
- Epidemiologically linked to a confirmed yellow fever case or visited/resided in an area with a high risk of yellow fever in the 2 weeks before onset of illness and
- No history of yellow fever vaccination

Confirmed:
A case that meets the clinical description as described above with the following:
- No history of yellow fever vaccination within 30 days before onset of illness, unless there is molecular evidence of infection with wild-type yellow fever virus, and any of the following:
  o Yellow fever virus identified by culture from tissue, blood, CSF, or other bodily fluid or
  o Yellow fever positive antigen from tissue, blood, CSF, or other bodily fluid or
  o Yellow fever nucleic acid (RNA) detected (example: PCR, sequencing, NAAT) from tissue, blood, CSF, or other body fluid

OR

- No history of yellow fever vaccination within 30 days before onset of illness and
  o At least a four-fold change (increase or decrease) of yellow fever virus-specific neutralizing antibody titer (example: PRNT, ELISA) in paired acute and convalescent sera

OR

- No history of yellow fever vaccination and
  o Yellow fever positive IgM antibody from CSF or serum and
  o Yellow fever positive neutralizing antibody (example: PRNT, ELISA) in the same specimen as the positive IgM or a later specimen

Critical Reporting Elements
Document relevant travel and deployment history occurring within the incubation period.
Note the patient’s yellow fever immunization history.
Comments

None.

Last update: January 2022
**Zika Virus (Flavivirus)**

**Background**

<table>
<thead>
<tr>
<th>Causative Agent</th>
<th>Zika virus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel Risks</td>
<td>Most common in Cape Verde, Mexico, the Caribbean, South and Central America, and parts of the Pacific Islands; possibly endemic in Africa, and Asia</td>
</tr>
<tr>
<td>Clinical Description</td>
<td>An emerging infection classified as two clinical types:</td>
</tr>
</tbody>
</table>

**Zika Virus Infection, Non-congenital:** Symptoms may include any of the following:
- Acute onset of fever, maculopapular rash, arthralgia, or conjunctivitis or
- Complication of pregnancy:
  - fetal loss in a mother who meets the clinical description of Zika virus or possess epidemiologic risk factors or
  - in utero findings of microcephaly or
- Guillain-Barre syndrome of unknown etiology

**Zika Virus Infection, Congenital:** An infant with microcephaly, intracranial calcifications, or central nervous system abnormalities.

**Case Classification**

**Zika Virus Infection, Non-congenital**

**Probable:**
A case with **ALL** of the following:
- Meets the exposure criteria* as described below and
- Zika virus positive IgM antibody from serum or CSF with any of the following:
  - Dengue virus negative IgM antibody and no Zika virus PRNT test performed or
  - Positive PRNT titer against Zika and Dengue (or other flavivirus endemic to the region where exposure occurred)

**Confirmed:**
A case with any of the following:
- Zika virus identified by culture from any acceptable clinical specimen or
- Zika virus positive antigen from any acceptable clinical specimen or
- Zika virus nucleic acid (RNA) detected (example: PCR, sequencing, NAAT) from any acceptable clinical specimen or
- Zika virus positive IgM antibody from serum or CSF with a positive PRNT titer against Zika **AND** a negative PRNT titer against Dengue (or other flavivirus endemic to the region where exposure occurred).

**Zika Virus Infection, Congenital**

**Probable:**
A case with **ALL** of the following:
- Mother meets the exposure criteria* described below or the laboratory criteria described above for Zika Virus Infection, Non-congenital and
• Zika virus positive IgM antibody from neonatal serum or neonatal CSF collected within 2 days of birth with any of the following:
  o Dengue virus negative IgM antibody and no Zika virus PRNT test performed or
  o Positive PRNT titer against Zika and Dengue (or other flavivirus endemic to the region where exposure occurred)

Confirmed:
A case with any of the following:
• Zika virus identified by culture from any acceptable neonatal clinical specimen collected within 2 days of birth or
• Zika virus positive antigen from any acceptable neonatal clinical specimen collected within 2 days of birth or
• Zika virus nucleic acid (RNA) detected (example: PCR, sequencing, NAAT) from any acceptable neonatal clinical specimen collected within 2 days of birth or
• Zika virus positive IgM antibody from umbilical cord blood, neonatal serum, or neonatal CSF collected within 2 days of birth with a positive PRNT titer against Zika and a negative PRNT titer against Dengue (or other flavivirus endemic to the region where exposure occurred)

Critical Reporting Elements
Specify the type of disease.
Document relevant travel and deployment history occurring within the incubation period.
Document the circumstances under which the case patient was exposed including duty exposure, occupational activities, environmental exposures, or other high risk activities.

Comments
*Exposure is defined as one or more of the following:
• Resides in or recent travel to an area with known Zika virus transmission or
• Sexual contact with a confirmed or probable case within the infection transmission risk window of Zika infection or
• Sexual contact with a person with recent travel to an area with known Zika virus transmission or
• Receipt of blood or blood products within 30 days of symptom onset or
• Organ or tissue transplant recipient within 30 days of symptom onset or
• Association in time and place with a confirmed or probable case or
• Likely vector exposure in an area with suitable seasonal and ecological conditions for potential local vector borne transmission.
**Required Data Elements**

To assure consistency of the Armed Forces data, this section lists the minimum required data elements for each report, along with recommended reporting guidelines for each element. Each Service may add its own additional data fields for internal analysis without compromising eventual data integration. These fields are all required in the Disease Reporting System internet (DRSi) for a medical event report to be submitted into the system.

**DEMOGRAPHIC DATA**

1. **Case Number**  
   Unique case identifier, automatically assigned by DRSi.

2. **Patient's First and Last Name**

3. **FMP and Patient Identification Number (SSN and/or DoD ID)**  
   Family member prefix code and SSN and/or DODID.

4. **Race/Ethnicity**  
   White, black, Hispanic, Asian, American Indian, other.

5. **Patient’s Sex**

6. **Rank**  
   E.g., E1, O1, CIV.

7. **Date of Birth**  
   Two-digit month, two-digit day, four-digit year.

8. **Sponsor Service Branch**

**MEDICAL DATA**

1. **Reportable Medical Event**

2. **Date of Onset**  
   If unsure of date of onset, date of presentation is an adequate substitute.

3. **Case Classification Status**  
   Confirmed, probable, or suspect. A description of each classification is provided within each RME case definition. Please note, not all RMEs have case definitions for each status – refer to the RME case definition when assigning the classification.

**ADDITIONAL INFORMATION RECOMMENDED FOR REPORTING**

**TRAVEL HISTORY**

Specify any recent travel the case may have had, when applicable. See individual case definitions to determine the time period for which reporting of travel destinations is required (generally between 1 – 2 incubation periods).

**COMMENTS**

Content will vary by condition; see case definitions for minimum suggested content. Comments are important for data interpretation and should be provided whenever possible.
<table>
<thead>
<tr>
<th>Condition</th>
<th>Synonyms</th>
<th>ICD-10 Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amebiasis</td>
<td></td>
<td>A06.0, A06.1, A06.2, A06.3, A06.4, A06.5, A06.6, A06.7, A06.81, A06.82, A06.89, A06.9</td>
</tr>
<tr>
<td>Anthrax</td>
<td></td>
<td>A22.0, A22.1, A22.2, A22.7, A22.8, A22.9</td>
</tr>
<tr>
<td>Arboviral Diseases</td>
<td>Japanese encephalitis; Tick-borne encephalitis (TBE); West Nile encephalitis/infection, Western equine encephalitis, Eastern equine encephalitis, St. Louis encephalitis, Australian encephalitis, California encephalitis, Rocio virus, Far Eastern tick-borne encephalitis, Central European tick-borne encephalitis, O’nyong-nyong fever, Venezuelan equine fever, Oropouche virus disease, Sandfly fever, Colorado tick fever</td>
<td>A83.0, A83.1, A83.2, A83.3, A83.4, A83.5, A83.6, A83.8, A83.9, A84.0, A84.1, A84.8, A84.9, A85.2, A92.1, A92.2, A92.30, A92.31, A92.32, A92.39, A92.8, A92.9, A93.0, A93.1, A93.2, A93.8, A94</td>
</tr>
<tr>
<td>Babesiosis</td>
<td></td>
<td>B60.0, B60.00, B60.01, B60.02, B60.03, B60.09</td>
</tr>
<tr>
<td>Botulism Toxin</td>
<td>Infant Botulism</td>
<td>A05.1, A48.51, A48.52</td>
</tr>
<tr>
<td>Brucellosis</td>
<td>Malta Fever; Mediterranean fever; Undulant fever</td>
<td>A23.0, A23.1, A23.2, A23.3, A23.8, A23.9</td>
</tr>
<tr>
<td>Campylobacteriosis</td>
<td>Vibrionic enteritis</td>
<td>A04.5</td>
</tr>
<tr>
<td>Chikungunya Virus Disease</td>
<td></td>
<td>A92.0</td>
</tr>
<tr>
<td>Chlamydia trachomatis</td>
<td></td>
<td>A56.00, A56.01, A56.02, A56.09, A56.11, A56.19, A56.2, A56.3, A56.4, A56.8</td>
</tr>
<tr>
<td>Cholera O1 or O139</td>
<td></td>
<td>A00.0, A00.1, A00.9</td>
</tr>
<tr>
<td>Coccidioidomycosis</td>
<td>Desert fever/rheumatism; San Joaquin valley fever; Valley fever</td>
<td>B38.0, B38.1, B38.2, B38.3, B38.4, B38.7, B38.81, B38.89, B38.9</td>
</tr>
<tr>
<td>Cold weather injuries</td>
<td>Frostbite; Immersion foot; Trench foot; Hypothermia</td>
<td>T33.011A, T33.011D, T33.011S, T33.012A, T33.012D, T33.012S, T33.019A, T33.019D, T33.019S, T33.02XA, T33.02XD, T33.02XS, T33.09XA, T33.09XD, T33.09XS, T33.1XXA, T33.1XXD, T33.1XXX, T33.2XXA, T33.2XXD, T33.2XXX, T33.3XXA, T33.3XXD, T33.3XXX, T33.40XA, T33.40XD, T33.40XS, T33.41XA, T33.41XD, T33.41XS, T33.42XA, T33.42XD, T33.42XS,</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>---------------------------</td>
<td></td>
</tr>
<tr>
<td>T33.511A</td>
<td>T33.511D, T33.511S, T33.512A, T33.512D, T33.512S, T33.519A, T33.519D, T33.519S, T33.521A, T33.521D, T33.521S, T33.522A, T33.522D, T33.522S, T33.529A, T33.529D, T33.529S, T33.531A, T33.531D, T33.531S, T33.532A, T33.532D, T33.532S, T33.539A, T33.539D, T33.539S, T33.60XA, T33.60XD, T33.60XS, T33.61XA, T33.61XD, T33.61XS, T33.62XA, T33.62XD, T33.62XS, T33.70XA, T33.70XD, T33.70XS, T33.71XA, T33.71XD, T33.71XS, T33.72XA, T33.72XD, T33.72XS, T33.811A, T33.811D, T33.811S, T33.812A, T33.812D, T33.812S, T33.819A, T33.819D, T33.819S, T33.821A, T33.821D, T33.821S, T33.822A, T33.822D, T33.822S, T33.829A, T33.829D, T33.829S, T33.831A, T33.831D, T33.831S, T33.832A, T33.832D, T33.832S, T33.839A, T33.839D, T33.839S, T33.90XA, T33.90XD, T33.90XS, T33.99XA, T33.99XD, T33.99XS, T34.011A, T34.011D, T34.011S, T34.012A, T34.012D, T34.012S, T34.019A, T34.019D, T34.019S, T34.02XA, T34.02XD, T34.02XS, T34.09XA, T34.09XD, T34.09XS, T34.1XXA, T34.1XXD, T34.1XXS, T34.2XXA, T34.2XXD, T34.2XXS, T34.3XXA, T34.3XXD, T34.3XXS, T34.40XA, T34.40XD, T34.40XS, T34.41XA, T34.41XD, T34.41XS, T34.42XA, T34.42XD, T34.42XS, T34.511A, T34.511D, T34.511S, T34.512A, T34.512D, T34.512S, T34.519A, T34.519D, T34.519S, T34.521A, T34.521D, T34.521S, T34.522A, T34.522D, T34.522S, T34.529A, T34.529D, T34.529S, T34.531A, T34.531D, T34.531S, T34.532A, T34.532D, T34.532S, T34.539A, T34.539D, T34.539S, T34.60XA, T34.60XD, T34.60XS, T34.61XA, T34.61XD, T34.61XS,</td>
<td></td>
</tr>
<tr>
<td>Diseases / Infections</td>
<td>ICD-10 Codes</td>
<td></td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>--------------</td>
<td></td>
</tr>
<tr>
<td>COVID-19</td>
<td>J12.82, U07.1, U07.2</td>
<td></td>
</tr>
<tr>
<td>Cryptosporidiosis</td>
<td>A07.2</td>
<td></td>
</tr>
<tr>
<td>Cyclosporiasis</td>
<td>A07.4</td>
<td></td>
</tr>
<tr>
<td>Dengue Virus Infections</td>
<td>Breakbone fever; Dengue hemorrhagic fever</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A90, A91</td>
<td></td>
</tr>
<tr>
<td>Diphtheria</td>
<td>A36.0, A36.1, A36.2, A36.3, A36.81, A36.82, A36.83, A36.84, A36.85, A36.86, A36.89, A36.9</td>
<td></td>
</tr>
<tr>
<td>Escherichia coli, Shiga toxin-producing</td>
<td>A04.3, B96.20, B96.21, B96.22, B96.23, B96.29</td>
<td></td>
</tr>
<tr>
<td>Ehrlichiosis and Anaplasmosis</td>
<td>Senetsu fever</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A77.40, A77.41, A77.49</td>
<td></td>
</tr>
<tr>
<td>Filarial Infections</td>
<td>Loa loa; Onchocerciasis; Loiasis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>B73.00, B73.01, B73.02, B73.09, B73.1, B74.0, B74.1, B74.2, B74.3, B74.8, B74.9</td>
<td></td>
</tr>
<tr>
<td>Giardiasis</td>
<td>A07.1</td>
<td></td>
</tr>
<tr>
<td>Gonorrhea</td>
<td>A54.00, A54.01, A54.02, A54.03, A54.09, A54.1, A54.21, A54.22, A54.23, A54.24, A54.29, A54.30, A54.31, A54.32, A54.33, A54.39, A54.40, A54.41, A54.42, A54.43, A54.49, A54.5, A54.6, A54.81, A54.82, A54.83, A54.84, A54.85, A54.86, A54.89, A54.9</td>
<td></td>
</tr>
<tr>
<td>Haemophilus influenza, Invasive</td>
<td>Haemophilus meningitis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A41.3, A49.2, B96.3, G00.0, J14, J20.1</td>
<td></td>
</tr>
<tr>
<td>Condition</td>
<td>Description</td>
<td>Code(s)</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>Hantavirus disease</td>
<td>Hemorrhagic fever with renal syndrome; Korean hemorrhagic fever</td>
<td>B33.4</td>
</tr>
<tr>
<td>Heat injuries</td>
<td>Heat exhaustion; Heat stroke</td>
<td>T67.0XXA, T67.0XXD, T67.0XXS, T67.3XXA, T67.3XXD, T67.3XXS, T67.4XXA, T67.4XXD, T67.4XXS, T67.5XXA, T67.5XXD, T67.5XXS</td>
</tr>
<tr>
<td>Hemorrhagic Fever, Viral</td>
<td>Crimean Congo fever; Ebola-Marburg disease; Guanarito virus; Junin virus; Kyasanur forest disease; Lassa fever; Machupo virus; Omsk hemorrhagic fever; Sabia virus</td>
<td>A98.0, A98.1, A98.2, A98.3, A98.4, A98.5, A98.8</td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>Catarrhal jaundice; Epidemic hepatitis/jaundice; Infectious hepatitis</td>
<td>B15.0, B15.9</td>
</tr>
<tr>
<td>Hepatitis B, acute &amp; chronic</td>
<td>Serum hepatitis</td>
<td>B16.0, B16.1, B16.2, B16.9, B17.0, B18.0</td>
</tr>
<tr>
<td>Hepatitis C, acute &amp; chronic</td>
<td>Parenterally transmitted non-A non-B hepatitis; Post transfusion non-A non-B hepatitis</td>
<td>B17.10, B17.11, B18.2, B19.20, B19.21</td>
</tr>
<tr>
<td>Influenza</td>
<td></td>
<td>J10.00, J10.01, J10.08, J10.1, J10.2, J10.81, J10.82, J10.83, J10.89, J11.00, J11.08, J11.1, J11.2, J11.81, J11.82, J11.83, J11.89</td>
</tr>
<tr>
<td>Legionellosis</td>
<td>Legionnaires disease; Pontiac fever</td>
<td>A48.1, A48.2</td>
</tr>
<tr>
<td>Leishmaniasis</td>
<td>Kala-azar</td>
<td>B55.0, B55.1, B55.2, B55.9</td>
</tr>
<tr>
<td>Leprosy</td>
<td>Hansen disease</td>
<td>A30.0, A30.1, A30.2, A30.3, A30.4, A30.5, A30.8, A30.9</td>
</tr>
<tr>
<td>Leptospirosis</td>
<td>Hemorrhagic jaundice; Mud fever; Weil disease</td>
<td>A27.0, A27.81, A27.89, A27.9</td>
</tr>
<tr>
<td>Listeriosis</td>
<td></td>
<td>A32.0, A32.11, A32.12, A32.7, A32.81, A32.82, A32.89, A32.9, P37.2</td>
</tr>
<tr>
<td>Lyme Disease</td>
<td>Tick-borne meningopolyneuritis</td>
<td>A69.20, A69.21, A69.22, A69.23, A69.29</td>
</tr>
<tr>
<td>Malaria</td>
<td></td>
<td>B50.0, B50.8, B50.9, B51.0, B51.8, B51.9, B52.0, B52.8, B52.9, B53.0, B53.8, B54</td>
</tr>
<tr>
<td>Measles</td>
<td>Hard measles; Morbilla; Red measles; Rubeola</td>
<td>B05.0, B05.1, B05.2, B05.3, B05.4, B05.81, B05.89, B05.9</td>
</tr>
<tr>
<td>Disease</td>
<td>Clinical Description</td>
<td>ICD-10 Codes</td>
</tr>
<tr>
<td>--------------------------</td>
<td>-----------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Norovirus</td>
<td>Norwalk-like virus; Norwalk-like agent</td>
<td>A08.11</td>
</tr>
<tr>
<td>Novel and Variant Influenza</td>
<td></td>
<td>J09.X1, J09.X2, J09.X3, J09.X9,</td>
</tr>
<tr>
<td>Pertussis</td>
<td>Whooping cough</td>
<td>A37.00, A37.01, A37.80, A37.81, A37.90, A37.91</td>
</tr>
<tr>
<td>Plague</td>
<td>Pestis</td>
<td>A20.0, A20.1, A20.2, A20.3, A20.7, A20.8, A20.9</td>
</tr>
<tr>
<td>Poliomyelitis</td>
<td>Infant paralysis</td>
<td>A80.0, A80.1, A80.2, A80.30, A80.39, A80.4, A80.9</td>
</tr>
<tr>
<td>Post-Exposure Prophylaxis (PEP) against Rabies</td>
<td></td>
<td>Z20.3, Z23.0, Z29.14</td>
</tr>
<tr>
<td>Q fever</td>
<td>Query fever</td>
<td>A78</td>
</tr>
<tr>
<td>Rabies, Human</td>
<td>Hydrophobia; Lyssa</td>
<td>A82.0, A82.1, A82.9</td>
</tr>
<tr>
<td>Relapsing Fever</td>
<td></td>
<td>A68.0, A68.1, A68.9</td>
</tr>
<tr>
<td>Rift valley fever</td>
<td></td>
<td>A92.4, A92.8, A92.9</td>
</tr>
<tr>
<td>Rubella</td>
<td>Congenital rubella syndrome; German measles</td>
<td>B06.00, B06.01, B06.02, B06.09, B06.81, B06.82, B06.89, B06.9, P35.0</td>
</tr>
<tr>
<td>Salmonellosis</td>
<td></td>
<td>A02, A02.0, A02.1, A02.2, A02.20, A02.21, A02.22, A02.23, A02.24, A02.25, A02.29, A02.8, A02.9</td>
</tr>
<tr>
<td>Schistosomiasis</td>
<td>Bilharziasis</td>
<td>B65.0, B65.1, B65.2, B65.3, B65.8, B65.9</td>
</tr>
<tr>
<td>Severe Acute Respiratory Syndrome</td>
<td>SARS; SARS-CoV</td>
<td>B97.21, J12.81</td>
</tr>
<tr>
<td>Shigellosis</td>
<td>Bacillary dysentery</td>
<td>A03.0, A03.1, A03.2, A03.3, A03.8, A03.9</td>
</tr>
<tr>
<td>Smallpox</td>
<td></td>
<td>B03</td>
</tr>
<tr>
<td>Spotted Fever Rickettsia</td>
<td>Sao Paolo fever; Rickettsia</td>
<td>A77.0</td>
</tr>
<tr>
<td>Syphilis</td>
<td>Lues</td>
<td>A50.01, A50.02, A50.03, A50.04, A50.05, A50.06, A50.07, A50.08, A50.09, A50.1, A50.2, A50.30, A50.31, A50.32, A50.39, A50.40, A50.41, A50.42, A50.43, A50.44, A50.45, A50.49, A50.51, A50.52, A50.53, A50.54, A50.55, A50.56, A50.57, A50.59, A50.6, A50.7, A50.9, A51.0, A51.1, A51.2, A51.32, A51.39, A51.41, A51.42, A51.43, A51.44, A51.45,</td>
</tr>
<tr>
<td>Disease</td>
<td>Description</td>
<td>ICD-10 Codes</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>--------------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Tetanus</td>
<td>Lockjaw</td>
<td>A33, A34, A35</td>
</tr>
<tr>
<td>Toxic shock syndrome</td>
<td>Streptococcal toxic shock syndrome</td>
<td>A48.3</td>
</tr>
<tr>
<td>Trichinosis</td>
<td>Trichinelliosis; Trichiniasis</td>
<td>B75</td>
</tr>
<tr>
<td>Trypanosomiasis</td>
<td>Chagas’ disease; Sleeping sickness</td>
<td>B56.0, B56.1, B56.9, B57.0, B57.1, B57.2, B57.30, B57.31, B57.32, B57.39, B57.40, B57.41, B57.42, B57.49, B57.5</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td></td>
<td>A15.0, A15.5</td>
</tr>
<tr>
<td>Typhoid fever</td>
<td>Enteric fever; Typhus abdominalis</td>
<td>A01.00, A01.01, A01.02, A01.03, A01.04, A01.05, A01.09, A01.1, A01.2, A01.3, A01.4</td>
</tr>
<tr>
<td>Typhus fever</td>
<td>Boutonneuse fever; South African tick typhus; Tsutsugamushi; Typhus exanthematicus</td>
<td>A75.0, A75.1, A75.2, A75.3, A75.9</td>
</tr>
<tr>
<td>Varicella</td>
<td>Chickenpox</td>
<td>B01.0, B01.11, B01.12, B01.2, B01.81, B01.89, B01.9</td>
</tr>
<tr>
<td>Yellow fever</td>
<td></td>
<td>A95.0, A95.1, A95.9</td>
</tr>
<tr>
<td>Zika Virus</td>
<td></td>
<td>A92.8</td>
</tr>
</tbody>
</table>
References